documents incorporated reference table c parts portions registrant 's annual report shareholders ii fiscal year annual report part iii portions registrant 's proxy statement annual meeting proxy statement table part table caption item c c business general segments business consumer pharmaceutical medical devices diagnostics geographic areas raw materials patents trademarks seasonality competition research environment regulation available information properties legal proceedings submission matters vote security holders executive officers registrant part ii market registrant 's common equity related stockholder matters selected financial data management 's discussion analysis results operations financial condition subsequent event quantitative qualitative disclosures market risk financial statements supplementary data changes disagreements accounting financial disclosure controls procedures part iii directors executive officers registrant executive compensation security ownership certain beneficial owners management certain relationships related transactions principal accountant fees services part iv exhibits financial statement schedules reports form k signatures report independent auditors financial statement schedule exhibit index table part item business general johnson johnson employing approximately people worldwide engaged manufacture sale broad range products health care field operating companies conducts business virtually countries world johnson johnson 's primary interest historically currently products related human health wellbeing johnson johnson organized state new jersey johnson johnson organized principle decentralized management executive committee johnson johnson principal management group responsible operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices diagnostics business segments subsidiary within business segments exceptions managed citizens country located segments business johnson johnson 's worldwide business divided three segments consumer pharmaceutical medical devices diagnostics additional information required item incorporated herein reference narrative tabular graphic descriptions segments operating results management 's discussion analysis results operations financial condition pages johnson johnson 's annual report shareholders fiscal year annual report filed exhibit report consumer consumer segment manufactures markets broad range products used baby child care skin care oral wound care women 's health care fields well nutritional overthecounter pharmaceutical products major brands include aveeno skin care products bandaid brand adhesive bandages carefree panty shields clean clear teen skin care products johnson 's baby line products motrin ib ibuprofen products pepcid ac acid controller johnson johnson merck consumer pharmaceuticals co neutrogena skin hair care products splenda calorie sweetener stayfree sanitary protection products broad family tylenol acetaminophen products products marketed principally general public sold wholesalers directly independent chain retail outlets throughout world pharmaceutical pharmaceutical segment 's principal worldwide franchises antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology fields products distributed directly wholesalers health care professionals use prescription general public key products pharmaceutical segment include procrit epoetin alfa sold outside us eprex biotechnology derived product stimulates red blood cell production duragesic fentanyl transdermal system sold abroad durogesic atreatment chronic pain offers novel delivery system risperdal risperidone risperdal consta risperidone longacting injection treatment symptoms schizophrenia remicade infliximab novel monoclonal antibody therapy indicated treat symptoms crohn 's disease rheumatoid arthritis levaquin levofloxacin floxin ofloxacin antiinfective field topamax topiramate antiepileptic ortho evra norelgestrominethinyl estradiol transdermal system first contraceptive patch approved food drug administration fda doxil doxorubicin anticancer treatment ditropan xl oxybutynin chloride treatment overactive bladder reminyl galantamine patients mild moderate alzheimer 's disease natrecor nesiritide novel agent approved congestive heart failure medical devices diagnostics medical devices diagnostics segment includes broad range products used direction physicians nurses therapists hospitals diagnostic laboratories clinics products include ethicon 's wound care women 's health products ethicon endosurgery 's minimally invasive surgical products cordis ' circulatory disease management products lifescan 's blood glucose monitoring products orthoclinical diagnostics ' professional diagnostic products depuy 's orthopaedic joint reconstruction spinal products vistakon 's disposable contact lenses distribution health care professional markets done directly surgical supply dealers geographic areas international business johnson johnson conducted subsidiaries located countries outside united states selling products virtually countries throughout world products made sold international business include many described business consumer pharmaceutical medical devices diagnostics however principal markets products methods distribution international business vary country culture products sold international business include developed united states also developed subsidiaries abroad investments activities countries outside united states subject higher risks comparable us activities investment commercial climate influenced restrictive economic policies political uncertainties raw materials raw materials essential johnson johnson 's operating companies ' businesses generally readily available multiple sources patents trademarks johnson johnson made practice obtaining patent protection products processes possible johnson johnson owns licensed number patents relating products manufacturing processes aggregate believed material importance operation business sales procrit risperdal accounted johnson johnson 's total revenues accordingly patents related products believed material relation johnson johnson whole next two years eprex duragesic certain contraceptive products lose basic patent protection subject generic competition expiration product patent typically results loss market exclusivity result significant reduction sales sales products account approximately johnson johnson 's annual worldwide sales johnson johnson made practice selling products trademarks obtaining protection trademarks available means johnson johnson 's trademarks protected registration united states countries products marketed johnson johnson considers trademarks aggregate material importance operation business seasonality worldwide sales reflect significant degree seasonality however spending heavier fourth quarter year quarters reflects increased spending decisions principally advertising research grantscompetition product lines johnson johnson companies compete companies large small located united states abroad competition strong lines without regard number size competing companies involved competition research involving development new products processes improvement existing products processes particularly significant results time time product process obsolescence development new improved products important johnson johnson 's success areas business competitive environment requires substantial investments continuing research multiple sales forces addition winning retention customer acceptance products johnson johnson 's consumer businesses involve heavy expenditures advertising promotion selling research research activities important segments johnson johnson 's business major research facilities located united states also australia belgium brazil canada germany switzerland united kingdom costs johnson johnson 's worldwide research activities relating development new products improvement existing products technical support products compliance governmental regulations protection consumer amounted million fiscal years respectively costs charged directly income year incurred research sponsored johnson johnson environment past year johnson johnson companies subject variety federal state local environmental protection measures johnson johnson believes operations comply material respects applicable environmental laws regulations johnson johnson 's compliance requirements expected material effect upon capital expenditures earnings competitive position regulation johnson johnson 's business subject varying degrees governmental regulation countries operations conducted general trend toward regulation increasing stringency united states drug device diagnostics cosmetic industries long subject regulation various federal state local agencies primarily product safety efficacy advertising labeling exercise broad regulatory powers food drug administration fda continues result increases amounts testing documentation required fda clearance new drugs devices corresponding increase expense product introduction similar trends toward product process regulation also evident number major countries outside united states especially european economic community efforts continuing harmonize internal regulatory systems costs human health care continue subject study investigation regulation governmental agencies legislative bodies united states countries united states attention focused drug prices profits programs encourage doctors write prescriptions particular drugs recommend particular medical devices managed care become potent force market place likely increased attention paid drug medical device pricing appropriate drug medical device utilization quality health care also uncertainty impact medicare prescription drug improvement modernization act enacted latter part regulatory agencies whose purview johnson johnson operates administrative powers may subject johnson johnson actions product recalls seizure products civil criminal sanctions cases johnson johnson may deem advisable initiate product recalls voluntarily addition sales marketing practices health care industry come increased scrutiny government agencies state attorney generals resulting investigations prosecutions carry risk significant civil criminal penalties available information copies johnson johnson 's quarterly reports form q annual report current reports form k amendments foregoing provided without charge shareholder submitting written request secretary principal executive offices company calling company 's sec filings also available company 's website wwwinvestorjnjcomgovernance soon reasonably practicable electronically filed furnished sec addition charters audit committee compensation benefits committee nominating corporate governance committee board directors company 's principles corporate governance policy business conduct code business conduct ethics directors executive officers available website address provided without charge shareholder submitting written request provided item properties johnson johnson worldwide subsidiaries operate manufacturing facilities occupying approximately million square feet floor space manufacturing facilities used industry segments johnson johnson 's business approximately follows table caption square feet segment thousands c consumer pharmaceutical medical devices diagnostics worldwide total table within united states facilities used consumer segment pharmaceutical segment medical devices diagnostics segment johnson johnson 's manufacturing operations outside united states often conducted facilities serve one segment business locations manufacturing facilities major geographic areas world follows table caption number square feet geographic area facilities thousands c c united states europe western hemisphere excluding usa africa asia pacific worldwide total table addition manufacturing facilities discussed johnson johnson maintains numerous office warehouse facilities throughout world research facilities also discussed item business research johnson johnson generally seeks manufacturing facilities although principally locations abroad leased office warehouse facilities often leased johnson johnson 's properties maintained good operating condition repair well utilized information regarding lease obligations see note rental expense lease commitments notes consolidated financial statements annual report filed exhibit report segmentinformation additions johnson johnson 's property plant equipment contained annual report filed exhibit report item legal proceedings information set forth note legal proceedings notes consolidated financial statements annual report incorporated herein reference filed exhibit report form k company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state laws primary relief sought cost past future remediation feasible predict determine outcome proceedings opinion company proceedings would material adverse effect results operations cash flows financial position company item submission matters vote security holders applicable executive officers registrant listed executive officers johnson johnson march unless otherwise indicated employee company affiliates held position indicated past five years family relationships executive officers arrangement understanding executive officer person pursuant executive officer selected annual meeting board directors executive officers elected board hold office one year respective successors elected qualified earlier resignation removal information regard directors company including following executive officers directors incorporated herein reference pages johnson johnson 's proxy statement dated march proxy statement table caption name age position c c robert j darretta vice chairman board directors member executive committee chief financial officer russell c deyo member executive committee vice president administrationa michael j dormer member executive committee worldwide chairman medical devicesb roger fine member executive committee vice president general counselc colleen goggins member executive committee worldwide chairman consumer personal care groupd joann heffernan heisen member executive committee vice president chief information officere brian perkins member executive committee worldwide chairman consumer pharmaceuticals nutritionals groupf per peterson md phd member executive committee chairman pharmaceuticals research developmentg christine poon member executive committee worldwide chairman medicines nutritionalsh nicholas j valeriani member executive committee vice president human resources worldwide chairman diagnosticsi table table caption name age position c c william c weldon chairman board directors chief executiveofficer chairman executive committee table mr r c deyo joined company became associate general counsel became member executive committee vice president administration mr deyo become vice president general counsel april b mr j dormer joined company company group chairman worldwide franchise chairman depuy codman company acquired depuy inc time acquisition chief operating officer depuy inc since mr dormer served president depuy international ltd mr dormer became member executive committee franchise group chairman medical devices april mr dormer named worldwide chairman medical devices group c mr r fine joined company became member executive committee vice president administration vice president general counsel mr fine retire april ms c goggins joined company held various positions becoming president personal products company named president johnson johnson consumer products company company group chairman north america johnson johnson consumer products ms goggins became member executive committee worldwide chairman consumer personal care group e ms j h heisen joined company became treasurer controller became member executive committee vice president chief information officer f mr b perkins joined company held various positions becoming president mcneil consumer products company company group chairman otc pharmaceuticals became member executive committee worldwide chairman consumer pharmaceuticals nutritionals group g dr p peterson joined company vice president drug discovery rw johnson pharmaceutical research institute named group vice president pharmaceutical research institute april president november dr peterson named chairman pharmaceuticals research development dr peterson became member executive committee h ms c poon joined company company group chairman pharmaceuticals group ms poon became member executive committee worldwide chairman pharmaceuticals group named worldwide chairman medicines nutritionals prior joining company served various management positions bristolmyers squibb years recently president international medicines president medical devices mr n j valeriani joined company held various positions becoming president ethicon endosurgery inc january named company group chairman ethicon endosurgery additional responsibility johnson johnson medical products medical devices diagnostics business canada became worldwide franchise chairman depuy franchise mr valeriani became member executive committee vice president human resources september february assumed additional responsibilities worldwide chairman diagnostics part ii item market registrant 's common equity related stockholder matters march approximately record holders common stock company information called item incorporated herein reference material captioned management 's discussion analysis results operations financial condition share repurchase dividends common stock market prices note notes consolidated financial statements annual report filed exhibit report item selected financial data information called item incorporated herein reference material captioned summary operations statistical data annual report filed exhibit report form k item management 's discussion analysis results operations financial condition information called item incorporated herein reference narrative tabular graphic material included material captioned management 's discussion analysis results operations financial condition pages annual report filed exhibit report subsequent event february company 's cordis operating company announced entered strategic alliance guidant corporation copromotion drugeluting stents advancement new technology coronary stent delivery systems sales marketing resources companies join forces focus promoting cypher sirolimuseluting coronary stent united states option pursue similar arrangement japan future companies collaborate marketing sales strategies associated cypher stent bear marketing sales costs separately cordis continue report cypher stent sales revenue cordis also obtain access guidant 's current next generation technologies delivery coronary stents guidant cordis immediately initiate development regulatory plans cypher stent utilizes guidant stent delivery system addition outstanding patent disputes companies settled described note legal proceedings notes consolidated financial statements filed exhibit report item quantitative qualitative disclosures market risk information called item incorporated herein reference material captioned management 's discussion analysis results operations financial condition liquidity capital resources pages annual report filed exhibit report form k item financial statements supplementary data see consolidated financial statements notes thereto material captioned report independent auditors incorporated reference pages annual report filed exhibit report item changes disagreements accountants accounting financial disclosure applicable item controls procedures disclosure controls end fiscal fourth quarter company evaluated effectiveness design operation disclosure controls procedures company 's disclosure controls procedures designed ensure company records processes summarizes reports timely manner information company must disclose reports filed securities exchange act william c weldon chairman chief executive officer robert j darretta vice chairman chief financial officer reviewed participated evaluation based evaluation messrs weldon darretta concluded date evaluation company 's disclosure controls procedures effective internal control fiscal quarter ended december significant changes company 's internal control financial reporting materially affected reasonably likely materially affect company 's internal control part iiiitem directors executive officers registrant information called item incorporated herein reference material caption election directors nominees pages proxy statement b material part hereof caption executive officers registrant c discussion audit committee heading directors ' fees committees meetings pages proxy statement material caption section beneficial ownership reporting compliance proxy statement company 's policy business conduct covers employees including chief executive officer chief financial officer controller meets requirements sec rules promulgated section sarbanesoxley act policy business conduct available company 's website wwwjnjcom copies policy business conduct available shareholders without charge upon written request secretary company 's principal address substantive amendment policy business conduct waiver policy granted chief executive officer chief financial officer controller also posted company 's website wwwjnjcom within five business days retained website least one year addition company adopted code business conduct ethics members board directors executive officers code business conduct ethics directors executive officers available company 's website wwwjnjcom copies code business conduct ethics available shareholders without charge upon written request secretary company 's principal address substantive amendment code waiver code granted member board directors executive officer also posted company 's website wwwjnjcom within five business days retained website least one year item executive compensation information called item incorporated herein reference following sections proxy statement election directors directors ' fees committees meetings pages compensation benefits committee report executive compensation pages shareholder return performance graphs pages executive compensation pages item security ownership certain beneficial owners management information called item incorporated herein reference material captioned election directors stock ownershipcontrol pages proxy statement note notes consolidated financial statements annual report filed exhibit report item certain relationships related transactions applicable item principal accountant fees services information called item incorporated herein reference material headings appointment independent auditors preapproval audit nonaudit services pages proxy statement part iv item exhibits financial statement schedules reports form k following documents filed part report financial statements following consolidated financial statements notes thereto independent auditor 's report pages annual report shareholders fiscal year incorporated herein reference filed exhibit report consolidated balance sheets end fiscal years consolidated statements earnings fiscal years consolidated statements equity fiscal years consolidated statements cash flows fiscal years notes consolidated financial statements report independent auditors financial statement schedules schedule ii valuation qualifying accounts schedules listed omitted required applicable exhibits required filed item l regulation sk information called item incorporated herein reference exhibit index report b reports form k report form k furnished january included press release announcing decision james lenehan retire company june resign vice chairman board directors president effective february report form k furnished january included press release dated january announcing company 's sales earnings fourth quarter fiscal year ended december including consolidated financial results report form k furnished march included press release announcing company 's cordis subsidiary entered strategic alliance guidant corporation respect cypher drugeluting stent report form k filed march included management 's discussion analysis financial condition results operations audited consolidated financial statements notes thereto report independent auditors december johnson johnson subsidiaries schedule ii valuation qualifying accounts fiscal years ended december december december dollars millions table caption additions balance charged deductions reserves balance beginning costs end period expensesa description amount period c c c c c reserves deducted accounts receivable trade reserve doubtful accounts writeoffs less recoveries currency adjustments reserve customer rebates customer rebates allowed currency adjustments reserve cash discounts cash discounts allowed currency adjustments reserves deducted accounts receivable trade reserve doubtful accounts writeoffs less recoveries currency adjustments reserve customer rebates customer rebates allowed currency adjustments reserve cash discounts cash discounts allowed currency adjustments reserves deducted accounts receivable trade reserve doubtful accounts writeoffs less recoveries currency adjustments reserve customer rebates customer rebates allowed currency adjustments reserve cash discounts cash discounts allowed currency adjustments table charges related customer rebates cash discounts reflected reductions sales customers signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized date march johnson johnson registrant w c weldon w c weldon chairman board directors chief executive officer pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated table caption signature title date c c w c weldon chairman board directors march chief executive officer w c weldon director principal executive officer r j darretta vice chairman board directors march chief financial officer director r j darretta principal financial officer j cosgrove controller march j cosgroves g n burrow director march g n burrow coleman director march coleman j g cullen director march j g cullen j folkman director march j folkman jordan director march jordan g langbo director march g langbo table table caption signature title date c c l lindquist director march l lindquist lf mullin director march lf mullin reinemund director march reinemund satcher director march satcher h b schacht director march h b schacht table report independent auditors financial statement schedule shareholders board directors johnson johnson audits consolidated financial statements referred report dated january except fifth thirteenth paragraphs note dates february february respectively appearing annual report shareholders johnson johnson report consolidated financial statements incorporated reference annual report also included audit financial statement schedule listed item opinion financial statement schedule presents fairly material respects information set forth therein read conjunction related consolidated financial statements pricewaterhousecoopers llp pricewaterhousecoopers llpnew york new york january exhibit index table caption reg sk exhibit table description item exhibit c ai restated certificate incorporation dated april incorporated herein reference exhibit registrant 's annual report year ended december aii certificate amendment restated certificate incorporation company dated may incorporated herein reference exhibit registrant 's annual report year ended january aiii certificate amendment restated certificate incorporation company dated may incorporated herein reference exhibit aiii registrant 's annual report year ended december aiv certificate amendment restated certificate incorporation company effective may incorporated herein reference exhibit registrant 's form q quarterly report quarter ended july b bylaws company amended effective june incorporated herein reference exhibit registrant 's form q quarterly report quarter ended july upon request securities exchange commission registrant furnish copy instruments defining rights holders long term debt registrant stock option plan nonemployee directors incorporated herein reference exhibit registrant 's annual report year ended december b stock option plan amended incorporated herein reference exhibit b registrant 's annual report year ended december c stock option plan amended incorporated herein reference exhibit b registrant 's annual report year ended january stock option plan amended incorporated herein reference exhibit c registrant 's annual report year ended december e stock compensation plan incorporated herein reference exhibit e registrant 's annual report year ended december f executive incentive plan amended incorporated herein reference exhibit f registrant 's annual report year ended december g domestic deferred compensation certificate extra compensation plan amended filed document h deferred fee plan directors amended incorporated herein reference exhibit h registrant 's annual report year ended december executive income deferral plan amended filed document j excess savings plan incorporated herein reference exhibit j registrant 's annual report year ended december k supplemental retirement plan incorporated herein reference exhibit h registrant 's annual report year ended january l executive life insurance plan incorporated herein reference exhibit registrant 's annual report year ended january stock option gain deferral plan incorporated herein reference exhibit registrant 's form kannual report year ended january table table caption reg sk exhibit table description item exhibit c n estate preservation plan incorporated herein reference exhibit n registrant 's annual report year ended january letter agreement dated june company mr r larsen respect postemployment arrangements incorporated herein reference exhibit registrant 's annual report year ended december p consulting agreement company dr judah folkman member board incorporated herein reference exhibit p registrant 's annual report year ended december statement computation ratio earnings fixed charges filed document pages company 's annual report shareholders fiscal year portions annual report incorporated reference report deemed filed filed document subsidiaries filed document consent independent accountants filed document certification chief executive officer rule aa securities exchange act pursuant section sarbanesoxley act filed document b certification chief financial officer rule aa securities exchange act pursuant section sarbanesoxley act filed document certification chief executive officer pursuant section sarbanesoxley act furnished document b certification chief financial officer pursuant section sarbanesoxley act furnished document annual reports form k johnson johnson savings plans filed june b cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements filed document table management contracts compensatory plans arrangements required filed exhibits form pursuant item c report form k copy exhibits listed provided without charge shareholder submitting written request specifying desired exhibits secretary principal executive offices company text document document typeexg sequence filenameyexvwgtxt descriptiondomestic deferred compensation plan text exhibit g johnson johnson certificate extra compensation planwitnesseth whereas johnson johnson company wishes reward employees well employees subsidiaries employee faithful service past particularly encourage employees future work permitting employees share growth success company 's enterprises issuing shares certificates extra compensation cec shares end receive extra compensation sums based upon measured amount cash dividends time time declared upon equal number shares common stock company common stock b formula value cec shares established pursuant article ninth plan formula value time termination employment death employment therefore consideration premises promises herein contained long employee shall remain employee agreed first number cec shares designated upon employee 's extra compensation shall based aggregate number cec shares awarded employee accordance plan evidenced written records company second employee remains employee company shall pay employee date paid cash dividend company 's common stock sum equivalent cash dividend multiplied total number cec shares designated employee employee employee record date dividend third event employee 's death employee company shall pay employee 's beneficiary last recorded employee 's signature records company sum money shall determined percentage formula value cec shares percentage shall based upon period elapsing date cec share awarded death follows event death within eighteen months date award event death eighteen months within fortytwo months date award event death fortytwo months date award event termination employee 's employment retirement physical mental disability otherwise except reason death company shall pay employee sum money shall determined percentage formula value cec shares purposes plan term retirement shall mean termination employment following employee 's entitlement normal retirement early retirement benefits consolidated retirement plan johnson johnson successor pursuant terms plan effect date employee terminates employment purposes plan employee placed longterm disability considered employee percentage shall based upon period elapsing date cec share awarded termination employment follows event termination within twelve months date award event termination twelve months within twentyfour months date award event termination twentyfour months within thirtysix months date award event termination thirtysix months within fortyeight months date award event termination fortyeight months within sixty months date award event termination sixty months date award company shall pay sum money due article third single lump sum unless employee made timely deferral electionpursuant provisions article seventh defer receipt sum upon hisher retirement retired pursuant definition retirement article third fourth election employee made provided payment sum due employee upon hisher retirement may deferred paid either single lump sum installments lump sum payment may deferred ten taxable years following employee 's retirement date installment payments elected first installment payment may made immediately upon retirement deferred ten taxable years installment payments made annually manner described approximately equal installment amounts ie value cec payout balance plus accrued interest divided number remaining installments minimum number annual installments two maximum number fifteen employee may elect defer value hisher total cec holdings retirement percentage increment less following rules shall apply respect payments immediate lump sum payment employee receive full value hisher cec holdings calendar month hisher retirement effective date employees retiring prior determination prior years cec value receive estimated value remainder paid shortly final value determined b deferred lump sum payment employee receive full value hisher cec holdings plus accrued interest january year heshe elects receive payment c immediate commencement installments employee receive first installment calendar month hisher retirement effective date subsequent installments plus accrued interest paid january year deferred commencement installments employee receive first subsequent installments plus accrued interest january year fifth respect portion formula value employee 's cec holdings hisher retirement date deferred andor paid installments interest shall paid company effective date retirement date payment interest rate deferred amounts shall fixed employee 's date retirement interest rate shall determined treasurer company sole discretion based yield curve activelytraded united states government debt date retirement period comparable length period deferral installmentsthe rate shall rounded decimal place interest shall compounded semiannually last calendar day june december year established interest rate shall remain fixed period deferral sixth event death employee whether prior termination hisher employment company make payment full balance plus accrued interest soon administratively practical single lump sum payment designated beneficiary seventh election employee defer payment elect installments part formula value hisher cec holdings hisher retirement date beyond hisher effective retirement date must made minimum twelve months prior date retirement date election may revised revoked twelve months prior retirement date twelve month period prior retirement date election irrevocable thus may revoked otherwise revised company may disallow employee 's desire defer payments andor elect installments determines participation would jeopardize plan 's compliance applicable law plan 's status top hat plan erisa election defer payment andor paid installments effective filed administrator referred article fifteenth form utilized purpose election made required deadline shall disregarded election defer andor paid installments made consultation employee 's tax andor financial advisor eighth number cec shares designated upon based measured extra compensation employee shall increasedproportionately time time extent stock split dividend common stock declared paid upon issued outstanding common stock company likewise number cec shares shall reduced proportionately time time extent number cec shares issued outstanding common stock company reduced reorganization reduction capital otherwise ninth purposes article third agreement formula value cec shares shall determined company 's board directors shall except event mentioned determine formula value sum onehalf asset value per share common stock plus onehalf earningpower value per share common stock calculated follows sum onehalf consolidated net asset value per share common stock assets per share less liabilities including reserves surplus reserve per share assets liabilities appear books company subsidiaries fiscal year end immediately preceding date valuation plus onehalf consolidated earningpower value per share common stock determined average annual net earnings per share common stock taxes net earnings appear books company subsidiaries five fiscal years preceding date valuation capitalized return capital invested eight percent ie multiple twelve onehalf times average earnings per share purpose foregoing calculation books company subsidiaries shall conclusive method consolidation shall adopted company preparing last previous annual report stockholders including appropriate provision taxes foreign domestic might incurred remitting income subsidiaries company decisions company 's treasurer times time time procedures adopted maintaining books company subsidiaries preparation balance sheets income statements method adjustments made consolidation matters accounting practice procedures shall conclusive event shall opinion board directors company calculation made provided result true value date article third determination necessary board sole discretion may shall obligated vary formula formula value cec shares determined board directors shall may fifteenth year determine announce formula value cec shares immediately preceding fiscal year end purposes plan tenth dividends share values used herein measures extra compensation paid hereunder nothing herein contained shall construed agreement transfer employee hisher beneficiary shall either acquire virtue hisher awarded cec shares right title interest whatsoever company 's common stock eleventh right benefit cec shares awarded plan assignable company fund obligations created employee participation cec plan rather company makes unsecured promise pay obligations general corporate assets applies obligations active retired participants certificates representing cec shares issued instead number cec shares awarded shall recorded books company twelfth regular parttime employees working hours week shall considered employees plan change parttime status less hours week shall considered termination provided however event employee age employee shall purposes plan deemed elected retirement defined article third nothing contained plan shall construed alter present employment indefinite term terminable either employee company without prior advance notice thirteenth employee leaves company one subsidiaries request company work joint venture operation company one subsidiaries minority partnership interest may sole discretion management compensation committee considered employee solely purposes plan period three years following departure company arrangement may extended two additional years management compensationcommittee sole discretion determines best interest company person ceases employment joint venture operation without concomitant return employment company one subsidiaries person shall immediately considered terminated cease considered employee purposes plan fourteenth employee may designate one beneficiaries receive value hisher payout upon death beneficiary predecease employee beneficiary named amount designated beneficiary employee 's payout balance case may distributed employee 's estate beneficiary designations may made revised time submitting beneficiary designation form administrator set forth article sixteenth beneficiary beneficiaries indicated form shall supersede prior designation fifteenth first quarter calendar year statements sent active employees participating cec plan well retirees deferred cec holdings report active employees provide value cec holdings based prior years ' final cec value statement also include previously made deferral elections beneficiary designations report retirees provide deferred cec payout balance plus interest well deferred andor installment election beneficiary designations sixteenth cec plan administered extra compensation services department corporate headquarters company questions regard administration cec plan addressed board directors within discretion shall authority terminate amend plan cancel amend terms cec shares granted hereunder without necessity obtaining approval employees hold cec shares termination cancellation amendment shall effect reducing dollar value vested cec shares whether paid deferred less aggregate formula value fiscal year end immediately preceding termination cancellation amendment increasing vesting period article third cec shares delaying payment payments due cec share holders event termination plan cancellation cec shares granted hereunder company shall pay employee sum money shall determined accordance provisions article third relating termination employment due retirement physical mental disability otherwise except reason death payments provision shall made single lump sum within days termination cancellation text document document typeexi sequence filenameyexvwitxt descriptionexecutive income deferral plan amended text exhibit johnson johnson executive income deferral plan johnson johnson executive income deferral plan plan intended permit select group executives defer income would otherwise immediately payable various compensation andor incentive plans johnson johnson company administration plan administered compensation committee company 's board directors committee shall responsibility determining investments time time available plan shall review investment options least every three years committee shall make decisions affecting timing price amount deferred awards hereinafter defined participants subject section securities exchange act amended may otherwise delegate authority plan eligibility eligibility defer income amounts plan initially limited members executive committee thecompany committee may time time expand eligibility defer compensation plan executives company committee however authority refuse permit executive participate plan elect defer payments committee determines participation would jeopardize plan 's compliance applicable law plan 's status top hat plan erisa deferral income deferral account estate preservation plan participants may elect defer fifty percent annual salary ii one hundred percent cash andor stock awards company 's executive incentive plan iii one hundred percent dividend equivalents paid company 's certificate extra compensation cec plan iv one hundred percent dividend equivalents paid deferred gain shares company 's stock option gain deferral plan amounts deferred known deferred awards directed election participant either income deferral account estate preservation plan described participant 's decision defer plan must made september year prior commencement fiscal year compensation bonus incentive payment dividend equivalent monies deferred earned notwithstanding foregoing required notice period elections made respect amounts deferred iv shall governed notice election provisions stock option gain deferral plan election defer pursuant section shall effective timely filed extra compensation services form utilized purpose participant shall designate multiples deferred award portion allocated investment option available plan participant may change investment options deferred awards yet credited income deferral account month change effective first day month following month participant 's request change allocation filed extra compensation services determining maximum amounts deferred participant plan committee shall take account include commitment made participant estate preservation plan extent amount salary andor cash award company 's executive incentive plan insufficient meet prior deferral commitment made participant plan estate preservation plan deferral commitment plan shall reduced accordingly deferral commitment estate preservation plan funded full elections defer dividend equivalents company 's cec plan applied elections apply cec contracts reverse order issuance deferred awards shall held one account regardless form compensation plan earned upon ceasing employee company participant event participant 's death named beneficiary hisher estate shall entitled receive cash lump sum value hisher income deferral account date termination unless participant elected pursuant provisions section defer payment hisher income deferral account beyond retirement notwithstanding participant fiscal year named executive officer proxy statement reporting purposes reason hisher chief executive officer company one four highest compensated officers chief executive officer payment income deferral account otherwise due made year shall postponed date th day january following fiscal year provided however funds income deferral account shall deemed invested one year treasury bill rate described date retirement payment made investment income deferral accounts election participant amounts income deferral account may invested utilizing investment options set forth amounts deferred month including stock award valued credited participant 's income deferral account effective last day month amounts deferred estate preservation plan separate distinct amounts deferred income deferral accounts common stock equivalent units amounts elected deferred investment option shall converted equivalent units company 's common stock common stock compensation deferred invested common stock common stock equivalent units deferred awards except stock awards company 's executive incentive plan number common stock equivalent units shall determined bydividing amount compensation dividend equivalents deferred average high low prices common stock traded new york stock exchange trading day immediately preceding last trading day month reported bloomberg another financial reporting service selected company sole discretion company shall credit participant 's income deferral account effective last trading month number full partial shares company 's common stock determined deferred awards representing stock awards company 's executive incentive plan number common stock equivalent units shall determined dividing amount compensation would otherwise issued stock awards average high low prices common stock traded new york stock exchange trading day compensation committee board directors approves stock award executive incentive plan reported bloomberg another financial reporting service selected company sole discretion company shall credit participant 's income deferral account effective date number full partial shares company 's common stock determined notwithstanding foregoing time shall shares company 's common stock actually purchased earmarked income deferral account participant shall rights shareowner respect shares credited income deferral account number common stock equivalent units included participant 's income deferral account shall adjusted reflect payment dividends increases decreases market value would resulted funds equal deferred amount actually invested common stock value company 's common stock purposes investment redesignation described section shall closing price company 's common stock new york stock exchange trading day immediately preceding last trading day month participant 's redesignation request received extra compensation services reported determined shall effective last trading day month distributions cash value equivalent shares company 's common stock valued closing price company 's common stock new york stock exchange last trading date preceding distribution date reported determined event reorganization stock split stock dividend combination shares merger consolidation rights offering change corporate structure shares company committee shall make adjustment may deem appropriate number kind shares company 's common stock credited participants ' income deferral accounts b balanced fund amounts elected deferred option shall deemed invested credited investment rate return earned balanced fund option company 's savings plan successor fund however balanced fund shares shall purchased earmarked participant 's account c one year treasury bill rate amounts elected deferred option shall deemed invested interest bearing account bears interest one year treasury bill rate compounded monthly purposes plan one year treasury bill rate shall interest rate one year treasury bills last trading day preceding calendar year provided financial reporting service shall selected company sole discretion rate shall adjusted annually treasury bills actually purchased earmarked participant 's account redesignation investment options within income deferral account participant may redesignate amounts previously credited income deferral account among investment options available plan participants wish redesignate particular investment option may time redesignate investment option redesignation investments may take place days prior scheduled distribution plan following additional rules shall apply respect redesignation previously creditedamounts permitted frequencyredesignation participant may made consecutive twelve month period b amount extent redesignationredesignation participant must multiples investment redesignation made c timingredesignation shall take place effective first day month following month participant 's written redesignation received extra compensation services value company 's common stock purposes investment redesignation shall average high low trading price common stock new york stock exchange reported determined trading day immediately preceding last trading day prior month special rules redesignation common stock equivalent units previously credited income deferral account material nonpublic informationthe committee sole discretion advice counsel time may rescind redesignation common stock equivalent units redesignation made participant time redesignation possession material nonpublic information respect company b committee 's estimation benefited information timing redesignation committee 's determination shall final binding event rescission participant 's income deferral account shall returned status though redesignation occurred notwithstanding committee shall rescind redesignation facts reviewed participant general counsel company designee prior redesignation general counsel designee concluded participant possession material nonpublic information ii participant subject section b securities exchange act may redesignate income deferral account common stock equivalent units applicable window period respect release quarterly annual statements sales earnings company iii redesignation amounts income deferral account shall made common stock equivalent units within six months discretionary opposite way transaction common stock held participant company 's savings plan e estate preservation plan participants may transfer amounts income deferral account balance estate preservation plan accordance terms estate preservation plan however transferred estate preservation plan amounts may transferred back income deferral account distribution income deferral accounts participant 's employment terminated reason including death disability participant eligible retire active service company 's pension plan income deferral account automatically paid lump sum soon administratively feasible month following termination employment distributions cash value equivalent shares company 's common stock valued average high low trading prices common stock new york stock exchange reported determined trading day immediately preceding last trading day month employment terminated post retirement deferrals election participant made provided payment sum otherwise due participant upon hisher retirement may deferred paid either single lump sum installments lump sum payment may deferred ten taxable years following participant 's retirement date installment payments elected first installment payment may made immediately upon retirement deferred ten taxable years installment payments made annually manner described approximately equal installment amounts ie value balance income deferral account plus accrued interest divided number remaining installments minimum number annual installments two maximum number fifteen participant may elect defer value hisher total income deferral account retirement percentage increment less payment amounts income deferral account pursuant section shall subject provisions last sentence section following additional rules shall apply respect payments immediate lump sum payment participant receive full value income deferral account calendar month retirement effective date participants retiring prior determination prior years incentive plan award receive estimated value remainder paid shortly final value determined b deferred lump sum payment participant receive full value income deferral account plus accrued interest january year elects receive payment c immediate commencement installments participant receive first installment calendar month hisher retirement effective date subject provisions last sentence section subsequent installments plus accrued interest paid january year deferred commencement installments participant receive first subsequent installments plus accrued interest january year respect amounts deferred andor paid installments interest shall paid company effective date retirement date payment interest rate deferred andor installment payments participant shall fixed date retirement shall rate rounded decimal place offered reported financial reporting service company sole discretion shall select effective retirement date united states treasury instrument period comparable length period deferral andor installment payments interest shall compounded semiannually last calendar day june december year one instrument quoted average rates shall utilized way example election made receive installments eight years comparable eight year us treasury rate shall utilized election made defer commencement installments two years installments paid ten years comparable twelve year us treasury rate shall utilized established interest rate shall remain fixed period deferral andor installments event death participant following retirement company make payment full balance hisher income deferral account plus accrued interest soon administratively practical single lump sum payment designated beneficiary subject provisions last sentence section event deferral installment election made section total amount income deferral account paid accordance provisions section lump sum payment soon practical following participant 's retirement effective date election participant defer payment elect installments part hisher account beyond hisher effective retirement date must made minimum twelve months prior date retirement date election may revised revoked twelve months prior retirement date twelve month period prior retirement date election irrevocable thus may revoked otherwise revised notwithstanding plan 's inception exception made participants retirement effective date january december participants retirement effective date prior june deferral andor installment election must made minimum three months calendar year prior retirement date participants retirement date july december election must made least six months prior retirement date example participant retires april must make deferral andor installment election later december retirement date august election must made later january election defer andor receive installment payments may revised revoked prior lastpermissible date making election time election may revoked otherwise revised election defer payment andor paid installments effective timely filed extra compensation services form utilized purpose election made required deadline shall disregarded estate preservation plan described section participant may elect transfer portion balance income deferral account estate preservation plan accordance terms estate preservation plan event election participant 's income deferral account shall reduced directed participant december year transfer occur transfers income deferral account estate preservation plan shall made effective december year transfer shall irrevocable made pursuant terms split dollar life insurance agreement designated compensation committee otherwise upon terms conditions set compensation committee upon election participant transfer amounts income deferral account estate preservation plan participant shall deemed waived irrevocably rights benefits might due plan respect amounts transferred b addition terms set forth paragraph amounts participant 's income deferral account may transferred estate preservation plan order satisfy prior obligation participant connection estate preservation plan transfer shall made solely upon direction compensation committee upon determination compensation committee transfer necessary shall effected terms conditions voluntary transfer paragraph determined committee transfer necessary participant 's income deferral account shall reduced requisite amount december st year directed compensation committee upon determination compensation committee subsequent transfer amounts estate preservation plan participant shall deemed waived irrevocably rights benefits might due plan respect amounts transferred deductions distributions company deduct distribution amounts required withheld income social security tax purposes withholding done pro rata basis per investment company may also deduct amounts participant owes company reason beneficiary designations participant may designate one beneficiaries receive value hisher income deferral account upon death beneficiary predecease participant beneficiary named amount designated beneficiary participant 's balance case may distributed participant 's estate beneficiary designations may made revised time submitting beneficiary designation form extra compensation services amendments committee may amend plan time however amendment shall without consent participant materially adversely affect right obligation respect deferred award made theretofore miscellaneous company fund obligations created participant 's participation plan rather company makes unsecured promise pay obligations general corporate assets applies obligations active retired participants first quarter calendar year statements sent active participants participating plan well retirees deferral accounts statement also include previously made deferral elections beneficiary designations report retirees provide deferred payout balance plus interest well deferred andor installment election beneficiary designations plan shall administered extra compensation services department corporate headquarters company questions regard theadministration plan addressed election defer andor paid installments made consultation participant 's tax andor financial advisor text document document typeex sequence filenameyexvtxt descriptionstatement computation ratio earnings text exhibit johnson johnson subsidiaries statement computation ratio earnings fixed charges dollars millions table caption fiscal year ended december december december december january c c c c c determination earnings earnings provision taxes income fixed charges total earnings defined fixed charges rents interests fixed charges capitalized interest total fixed charges ratio earnings fixed charges table ratio earnings fixed charges represents historical ratio johnson johnson calculated total enterprise basis ratio computed dividing sum earnings provision taxes fixed charges excluding capitalized interest fixed charges fixed charges represent interest including capitalized interest amortization debt discount expense interest factor rentals consisting appropriate interest factor operating leases text document document typeex sequence filenameyexvtxt descriptionpages annual report shareholders text management 's discussion analysis results operations financial conditionorganization business segments description company business segments company subsidiaries approximately employees worldwide engaged manufacture sale broad range products health care field company conducts business virtually countries world primary interest historically currently products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices diagnostics consumer segment manufactures markets broad range products used baby child care skin care oral wound care women 's health care fields well nutritional overthecounter pharmaceutical products products marketed principally general public sold wholesalers directly independent chain retail outlets throughout world pharmaceutical segment includes products following therapeutic areas antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology areas products distributed directly wholesalers health care professionals prescription use general public medical devices diagnostics segment includes broad range products used principally professional fields physicians nurses therapists hospitals diagnostic laboratories clinics products include cordis ' circulatory disease management products depuy 's orthopaedic joint reconstruction spinal products ethicon 's wound care women 's health products ethicon endosurgery 's minimally invasive surgical products lifescan 's blood glucose monitoring products orthoclinical diagnostics ' products vistakon 's disposable contact lenses company 's structure based upon principle decentralized management executive committee johnson johnson principal management group responsible operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices diagnostics business segments subsidiary within business segments exceptions managed citizens country located product lines company competes companies large small located throughout world competition strong product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant periodically results product process obsolescence development new improved products important company 's success areas business competitive environment requires substantial investments continuing research multiple sales forces addition winning retention customer acceptance company 's consumer products involves significant expenditures advertising promotion management 's objectives company 's objective achieve superior levels capital efficient profitable growth accomplish company 's management operates business consistent certain strategic principles proven successful time end company participates growth areas human health care committed attaining leadership positions growth segments development innovative products services billion sales invested research development recognizing importance ongoing development new differentiated products services operating companies located countries company views principle decentralized management asset fundamental success broadly based business also fosters entrepreneurial spirit combining extensive resources large organization ability react quickly local market changes challenges businesses managed long term order sustain leadership positions achieve growth provides enduring source value shareholders unifying management team company 's dedicated employees achieving objectives johnson johnson credo credo provides common set values serves constant reminder company 's responsibilities customers employees communities shareholders company believes basic principles along overall mission improving quality life people everywhere enable johnson johnson continue among leaders health care industry company continued evaluate enhance existing internal control processes evaluate implement internal control reporting requirements sarbanesoxley act company recognizesthat must rely depend leadership management teams throughout johnson johnson family companies ensure successful compliance sarbanesoxley act additionally company continues maintain strong ethical environment using johnson johnson credo overall guide results operations analysis consolidated sales worldwide sales increased billion compared increases sales increases consist following table caption sales increase due c c c volume price currency total table sales us companies billion billion billion represents increase sales international companies billion billion billion represents increase graph last five years annual compound growth rates worldwide us international sales respectively tenyear annual compound growth rates worldwide us international sales respectively graph geographic areas throughout world posted doubledigit sales increases sales increased europe western hemisphere excluding us asiapacific africa regions sales gains include positive impact currency fluctuations us dollar foreign currencies europe asiapacific africa region negative impact due currency fluctuations western hemisphere excluding us sales three distributors mckesson hboc amerisourcebergen corp cardinal distribution accounted respectively total revenues amerisourcebergen corp accounted total revenues mckesson hboc cardinal distribution accounting revenues respectively graph analysis sales business segments consumer consumer segment sales billion increase operational growth accounting total growth due currency fluctuations us consumer segment sales billion increase international sales billion increase due operations due currency fluctuations consumer segment sales growth attributable strong sales performance major franchises segment including skin care baby kids care mcneil consumer overthecounter pharmaceutical nutritional products skin care franchise sales billion representing increase growth attributed solid sales neutrogena brand products especially international markets aveeno brand products facial care line well new products launched latter half baby kids care franchise grew billion growth franchise led new products launched including johnson 's softwash johnson 's softlotion mcneil consumer overthecounter pharmaceutical nutritional products sales billion increase contributing growth continued growth splenda brand calorie sweetener increased salesin motrin tylenol brand products due early strong cold flu season another franchise contributing overall sales growth consumer segment women 's health franchise achieved sales billion increase strong growth sanitary protection products international markets contributed growth franchise consumer segment sales billion increase increase due operational growth offset negative currency impact us sales increased international sales gains operational gains offset negative currency impact consumer segment sales billion increase increase due operational growth offset negative currency impact us sales increased international sales gains sales gains local currency offset negative currency impact pharmaceutical pharmaceutical segment sales billion increase change due operational growth remaining increase related positive impact currency us pharmaceutical segment sales increased international pharmaceutical segment sales increased included growth operationally related positive impact currency sales billion table caption change millions dollars vs vs c c c c c procriteprex epoetin alfa risperdal risperidone remicade infliximab duragesic fentanyl transdermal system hormonal contraceptives levaquinfloxin levofloxacin ofloxacin topamax topiramate table pharmaceutical segment sales growth reflects strong performance many key pharmaceutical products despite sales decline procrit epoetin alfa eprex epoetin alfa adversely affected competition label change combined procrit eprex sales declined compared decline net effect strong market growth positive currency impact offset loss market share company continues implement programs improve competitive position include steps ensure procrit priced competitively well conducting clinical development programs provide comparative data competitive products strong growth drivers pharmaceutical segment duragesic fentanyl transdermal system sold outside us durogesic novel delivery system treatment chronic pain continued achieve outstanding results growing last year currently litigation challenging patent exclusivity duragesic may may impact sales product event product expected face generic competition january see note discussion matter psychotropic central nervous system field risperdal risperidone medication treats symptoms schizophrenia accounted billion sales fueled successful launch risperdal consta risperidone longacting injection markets outside united states october product approved us food drug administration fda remicade infliximab novel monoclonal antibody therapy indicated treat symptoms crohn 's disease rheumatoid arthritis two autoimmune disorders accounted billion sales continued maintain leadership position growing autoimmune market antiinfective field including levaquin levofloxacin floxin ofloxacin also strong growth hormonal contraceptive franchise grew fueled ortho evra norelgestrominethinylestradiol first contraceptive patch approved fda also strong growth various brands including doxil doxorubicin anticancer treatment ditropan xl oxybutynin treatment overactive bladder reminyl galantamine hbr treatment patients mild moderate alzheimer 's disease acquisition scios inc biopharmaceutical company marketed product cardiovascular disease research projects focused autoimmune diseases also contributed pharmaceutical segment sales growth scios acquired strengthen company 's business key therapeutic areas technology platforms scios ' product natrecor nesiritide novel agent approved congestive heart failure several significant advantages existing therapies pharmaceutical segment sales billion increase due operations growth due currency fluctuations us sales increased international sales grew includes positive impact currency operational growth pharmaceutical segment sales billion total increase us sales increased international sales increased operational growth offset negative currency impact medical devices diagnostics worldwide medical devices diagnostics segment achieved sales billion representing increase prior year operational growth positive impact currency us sales increased international sales increased operations currency strong sales growth segment led cordis depuy franchises cordis franchise key contributor medical devices diagnostics segment results reported sales billion signifies growth prior year primary driver sales growth cypher sirolimuseluting stent approved us fda april device treatment coronary artery disease implanted approximately half million patients around world cypher drugeluting stent approved use us however product pending approval fda compete cypher sirolimuseluting stent depuy franchise reported billion sales represents growth prior year depuy 's orthopaedic joint reconstruction products including shoulder knee product lines primarily responsible growth global advantage system shoulder market continuing trend towards mobile bearings minimally invasive unicompartmental knees strong performance also reported area spinal orthobiologics led continued success new product sales acquisition orquest principal product healos bone graft substitute designed enhance fusion franchises contributed overall sales growth medical devices diagnostics segment include ethicon ethicon endosurgery lifescan orthoclinical diagnostics vision care franchises ethicon worldwide franchise reported billion sales growth rate prior year ethicon franchise continues grow introducing new products marketplace coated vicryl polyglactin plus first product new antibacterial suture platform ethicon endosurgery franchise reported billion sales growth rate prior year growth mainly driven endocutter sales include products used performing bariatric procedures treatment obesity important focus area ethicon endosurgery lifescan franchise reported billion sales growth rate prior year september lifescan launched upgraded onetouch basic test strip requires less blood insulin testing orthoclinical diagnostics franchise reported billion sales growth rate prior year growth mainly driven launch vitros eci ahavtotal assay measurement antibody hepatitis virusthe vision care franchise reported billion sales growth rate prior year led continued success japanese market worldwide sales billion medical devices diagnostics segment represented total increase total increase also represents operational sales increase prior year us sales international sales increased prior year worldwide sales billion medical devices diagnostics segment represented total increase operational sales gains offset negative currency impact us sales international sales increased operational sales gains offset negative currency impact analysis consolidated earnings provision taxes income consolidated earnings provision taxes income increased billion billion increase billion percent sales consolidated earnings provision taxes income represents decline improvement improvement sections follow highlight significant components changes consolidated earnings provision taxes income cost goods sold selling marketing administrative expenses cost goods sold selling marketing administrative expenses percent sales follows table caption sales c c c cost goods sold increasedecrease selling marketing administrative expenses increasedecrease table improvement percent sales selling marketing administrative expenses increase percent sales costs goods sold due changes mix products varying cost structures well cost retirement enhancement program million offered fourth quarter decreases attributable expense leveraging sales increases productivity improvements research development research activities represent significant part company 's business expenditures relate development new products improvement existing products technical support products compliance governmental regulations protection consumer worldwide costs research activities excluding inprocess research development charges follows table caption millions dollars c c c research expense percent increase prior year percent sales table research development expense percent sales pharmaceutical segment averaging consumer medical devices diagnostics segments combined respectively significant research activities continued pharmaceutical segment increasing billion compound annual growth rate approximately fiveyear period since johnson johnson pharmaceutical research development llc formerly operating two separate units janssen research foundation rw johnson pharmaceutical research institute primary worldwide pharmaceutical research organization additional research conducted centocor alza tibotecvirco nv scios inc collaboration james black foundation london england inprocess research development company recorded inprocess research development iprd charges million tax related acquisitions acquisitions included scios inc link spine group inc certain assets orquest inc dimensional pharmaceuticals inc scios inc biopharmaceutical company marketed product cardiovascular disease research projects focused autoimmune diseases acquisition scios inc accounted million tax iprd charges included operating profit pharmaceutical segment link spine group inc acquired provide company exclusive worldwide rights charite artificial disc treatment spine disorders acquisition link spine group inc accounted million tax iprd charges included operating profit medical devices diagnostics segment orquest inc biotechnology company focused developing biologicallybased implants orthopaedic spine surgery acquisition certain assets orquest inc accounted million tax iprd charges included operating profit medical devices diagnostics segment dimensional pharmaceuticals inc company technology platform focused discovery development potential new drugs early stage development inflammation acquisition dimensional pharmaceuticals inc accounted million tax iprd charges included operating profit pharmaceutical segment company recorded iprd charges million tax related acquisitions tibotecvirco nv privatelyheld biopharmaceutical company focused developing antiviral treatments obtech medical ag privately held company markets adjustable gastric band treatment morbid obesity iprd million million included pharmaceutical medical devices diagnostics group respectively company recorded iprd charges million tax incurred result acquisition inverness medical technology inc supplier lifescan 's electrochemical products blood glucose monitoring following spinoff nondiabetes businesses teramed inc early stage medical device company developing endovascular stentgraft systems minimally invasive treatment abdominal aortic aneurysms total iprd million included medical devices diagnostics segment income expense net income expense includes gains losses related sale writedown certain investments equity securities held johnson johnson development corporation gainslosses disposal fixed assets currency gains losses minority interests litigation settlement income expense royalty income change net income expense net income million income expense includes income arbitration ruling million related stent patent amount received fourth quarter included medical devices diagnostics segment operating profit also included medical devices diagnostics segment operating profit gain sale various product lines longer compatible segment 's strategic goals income expense also includes recovery million loan previously reserved included pharmaceutical segment operating profit income expense included gain sale ortho prefest product line impact amgen arbitration settlement october arbitrator chicago denied effort amgen inc terminate license agreement ortho biotech inc obtained exclusive us rights amgendeveloped erythropoetin epo indications outside kidney dialysis decision arbitrator found sales made markets amgen retained exclusive rights warrant extraordinary remedy terminating contract instead found amgen could adequately compensated monetary damages arbitrator awarded million damages january arbitrator ruled amgen prevailing party arbitration entitling award reasonable attorney 's fees costs company expensed million fourth quarter connection claim charges included pharmaceutical segment operating profit addition items indicated income expense included costs related merger alza million amortization expense approximately million longer required financial accounting standards board fasb standard goodwill intangible assets sfas operating profits segments business follows table caption percent segment sales millions dollars c c c c consumer pharmaceutical med devices diag segments total expenses allocated segments earnings provision taxes income table amounts allocated segments include interest incomeexpense minority interest general corporate income expense graph consumer segment operating profit consumer segment percent sales remained unchanged expense leveraging due increased sales volumes offset costs incurred manufacturing programs gain future efficiencies advertising consumer segment operating profit increased prior year reflects operating profit percent sales improvement improvement due primarily leveraging selling promotion administrative expenses offset increased expenditures advertising additionally consumer segment operating profit improved amortization expense goodwill certain trademarks longer required sfas pharmaceutical segment operating profit pharmaceutical segment percent sales reflecting decline due iprd charges related acquisitions previously noted additionally operating profit impacted sales decline high margin products procriteprex increased consumer promotional spending new products line extensions pharmaceutical segment operating profit increased reflects operating profit percent sales improvement operating profit negatively impacted cost amgen arbitration settlement million damages legal fees iprd related acquisitions offset gain sale ortho prefest product line impact sfas operating profit percent sales operating profit also included impact expenses related merger alza million medical devices diagnostics operating profit medical devices diagnostics segment percent sales reflecting improvement increased sales volume primarily due cypher stent sales driver medical devices diagnostics segment growth medical devices diagnostics segment operating profit increased reflecting operating profit percent sales improvement nonamortization goodwill certain trademarks accounted improvement remaining margin improvement prior year achieved despite investment spending support cordis product line operating profit also includes iprd related acquisitions interest income expense interest income decreased million due primarily basis point decrease average yield investments compared cash balance includes current marketable securities end billion averaged billion slightly higher billion average cash balance interest expense increased million compared primarily due increase average debt balance billion billion average interest rate outstanding debt decreased approximately basis points year year provision taxes income worldwide effective income tax rate increase effective tax rate years primarily due company 's nondeductible iprd charges increase income subject tax us refer note additional information liquidity capital resources cash flows cash generated operations selected borrowings provides major sources funds growth business including working capital capital expenditures acquisitions share repurchases dividends debt repayments cash flow operations billion increase billion major factors contributing increase increase net income billion increase iprd billion increase accounts payable accrued liabilities billion due primarily increase volume timing payments decrease pension funding billion changes deferred taxes billion detailed discussion change deferred taxes see note net cash used investing activities increased billion due acquisitions detailed discussion mergers acquisitions see note net cash used financing activities decreased billion due impact billion stock repurchase offset change net repayment debt billion financing activities also increases decreases longterm shortterm debt due financing acquisition scios inc company retired net billion commercial paper cash current marketable securities billion end compared billion end graph cash generated operations amounted billion less cash generated operations billion decrease due primarily funding us pension plan approximately billion net current tax benefit contractual obligations commitments company longterm contractual obligations primarily lease debt obligations unfunded retirement plans satisfy obligations company use cash operations following table summarizes company 's contractual obligations aggregate maturities december see notes details table caption unfunded operating debt retirement millions dollars leases obligations plans c c c table share repurchase dividends february company announced stock repurchase program billion time limit program program completed onaugust million shares repurchased aggregate price billion addition company annual program repurchase shares use employee stock employee incentive plans company increased dividend st consecutive year cash dividends paid per share compared dividends per share per share dividends distributed follows table caption c c c first quarter second quarter third quarter fourth quarter total table january board directors declared regular cash dividend per share payable march shareholders record february company expects continue practice paying regular cash dividends financing market risk company uses financial instruments manage impact foreign exchange rate changes cash flows accordingly company enters forward foreign exchange contracts protect value existing foreign currency assets liabilities hedge future foreign currency product costs gains losses contracts offset gains losses underlying transactions appreciation us dollar december market rates would increase unrealized value company 's forward contracts million conversely depreciation us dollar december market rates would decrease unrealized value company 's forward contracts million either scenario gain loss forward contract would offset gain loss underlying transaction therefore would impact future earnings cash flows company hedges exposure fluctuations currency exchange rates effect assets liabilities foreign currency entering currency swap contracts change spread us foreign interest rates company 's interest rate sensitive financial instruments would either increase decrease unrealized value company 's swap contracts approximately million either scenario maturity gain loss swap contract would offset gain loss underlying transaction therefore would impact future cash flows company enter financial instruments trading speculative purposes company policy entering contracts parties least equivalent credit rating counterparties contracts major financial institutions company significant exposure one counterparty management believes risk loss remote total unused credit available company approximates billion including billion credit commitments billion uncommitted lines various banks worldwide expire september may company issued total billion bonds shelf registration million debentures due may million debentures due may december company filed new shelf registration securities exchange commission combination million remaining prior shelf registration enables company issue billion unsecured debt securities warrants purchase debt new shelf registration became effective january johnson johnson continues one industrial companies triple credit rating total borrowings billion end net cash cash current marketable securities net debt billion net cash cash current marketable securities net debt billion total debt represented total capital shareholders ' equity andtotal debt total capital shareholders ' equity per share end compared yearend increase period ended december material cash commitments summary borrowings found note information critical accounting policies estimates management 's discussion analysis results operations financial condition based company 's consolidated financial statements prepared accordance accounting principles generally accepted us preparation financial statements requires management make estimates assumptions affect amounts reported revenues expenses assets liabilities related disclosures actual results may may differ estimates company 's significant accounting policies described note however company believes understanding certain key accounting policies essential achieving insight company 's operating results financial condition key accounting policies include revenue recognition income taxes legal self insurance contingencies valuation longlived assets assumptions used determine amounts recorded pensions employee benefit plans accounting stock options revenue recognition company recognizes revenue product sales goods shipped delivered title risk passes customer provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted reductions determining sales period related sales recorded provisions largest medicaid rebate provision based estimates derived current program requirements historical experience company also recognizes service revenue received copromotion certain products years presented service revenues less total revenues included product sales income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting us tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based current tax regulations rates changes tax laws rates may affect deferred tax assets liabilities recorded future management believes changes estimates would result material effect company 's results operations cash flows financial position company intends continue reinvest undistributed international earnings expand international operations therefore us tax expense recorded cover repatriation undistributed earnings december december cumulative amount undistributed international earnings approximately billion billion respectively legal self insurance contingencies company records accruals various contingencies including legal proceedings product liability cases arise normal course business accruals based management 's judgment probability losses opinions legal counsel applicable actuarially determined estimates additionally company records insurance receivable amounts third party insurers based probability recovery appropriate reserves receivables recorded estimated amounts may collected third party insurers longlived intangible assets company assesses changes economic conditions makes assumptions regarding estimated future cash flows evaluating value company 's fixed assets goodwill noncurrent assets assumptions estimates may change time may may necessary company record impairment charges employee benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide plans require assumptions discount rate expected return plan assets expected salary increases health care cost trend rates see note detail rates effect change rates company 's results operations stock options company elected use accounting principles board opinion accounting stock issued employees apb require compensation costs related stock options recorded net incomeas options granted various stock options plans exercise price equal market value underlying common stock grant date statement financial accounting standard sfas accounting stockbased compensation transition disclosure amendment fasb statement requires pro forma disclosure net income earnings per share determined fair value method accounting stock options applied measuring compensation cost see notes information regarding stock options new accounting standards june financial accounting standards board fasb issued statement financial accounting standard sfas accounting asset retirement obligations company adopted standard material impact company 's results operations cash flows financial position june fasb issued sfas accounting costs associated exit disposal activities effective exit disposal activities initiated december company 's adoption sfas material effect company 's results operations cash flows financial position november fasb issued fasb interpretation fin guarantor 's accounting disclosure requirements guarantees including indirect guarantees indebtedness others interpretation fasb statements rescission fasb interpretation fin clarifies requirements fasb statement accounting contingencies relating guarantor 's accounting disclosure issuance certain types guarantees disclosure requirements fin effective financial statements interim annual periods end december provisions initial recognition measurement effective prospective basis guarantees issued modified irrespective guarantor 's yearend fin requires upon issuance guarantee entity must recognize liability fair value obligation assumes guarantee company 's adoption fin material effect company 's results operations cash flows financial position january fasb issued fin consolidation variable interest entities interpretation arb december issued revised fin r consolidation variable interest entities interpretation arb address consolidation variable interest entities fin expanded criteria consideration determining whether variable interest entity consolidated business entity requires existing unconsolidated variable interest entities include limited special purpose entities spes consolidated primary beneficiaries entities effectively disperse risks among parties involved interpretation immediately applicable variable interest entities created january adoption portion fin material effect company 's results operation cash flows financial position fin applicable variable interest entities enterprise holds variable interest acquired february company various investments arrangements may may considered variable interests adoption fin anticipated material effect results operations cash flows financial position company april fasb issued sfas amendment statement derivative instruments hedging activities effective contracts entered modified june statement amends clarifies financial accounting reporting derivative instruments including certain derivative instruments embedded contracts hedging activities company 's adoption sfas material effect company 's results operations cash flows financial position may fasb issued sfas accounting certain financial instruments characteristics liabilities equity effective financial instruments entered modified may statement establishes standards issuer classifies measures certain financial instruments characteristics liabilities equity company 's adoption sfas material effect company 's results operations cash flows financial position december fasb issued sfas revised employers ' disclosures pensions postretirement benefits amendment fasb statement effective fourth quarter statement revises employers ' disclosures pension plans postretirement benefit plans disclosures included note december fasb issued fasb staff position fsp fas accounting disclosure requirements related medicare prescription drug improvement modernization act effective interim annual financial statements fiscal years ending december company elected defer adoption fsp fas allowed standard company 's adoption fsp fas expected material effect company 's results operations cash flows financial position economic market factors johnson johnson aware products used environment decade policymakers consumers businesses expressed concern rising cost health care response concerns johnson johnson long standing policy pricing products responsibly period united states weighted average compound annual growth rate johnson johnson price increases health care products prescription overthecounter drugs hospital professional products us consumer price index cpi inflation rates even though moderate many parts world continue effect worldwide economies consequently way companies operate face increasing costs company strives maintain profit margins cost reduction programs productivity improvements periodic price increases company faces various worldwide health care changes may result pricing pressures include health care cost containment government legislation relating sales promotions reimbursement december medicare prescription drug improvement modernization act enacted introduces prescription drug benefit medicare well subsidy sponsors retiree health care benefit plans company elected defer recognition act time authoritative guidance issued measures accumulated postretirement benefit obligation net periodic postretirement benefit cost company 's financial statements reflect effect act company also operates environment becoming increasingly hostile intellectual property rights generic drug firms filed abbreviated new drug applications seeking market generic forms company 's key pharmaceutical products prior expiration applicable patents covering products event company successful defending lawsuit resulting abbreviated new drug application filing generic firms introduce generic versions product issue resulting substantial market share revenue losses information see discussion litigation filers abbreviated new drug applications note common stock market prices company 's common stock listed new york stock exchange symbol jnj composite market price ranges johnson johnson common stock table caption high low high low c c c c first quarter second quarter third quarter fourth quarter yearend close table cautionary factors may affect future results annual report contains forwardlooking statements forwardlooking statements relate strictly historical current facts anticipate results based management 's plans subject uncertainty forwardlooking statements may identified use words like plansexpects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance company 's strategy growth product development regulatory approval market position expenditures forwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncertainties materialize actual results could vary materially company 's expectations projections investors therefore cautioned place undue reliance forwardlooking statements company assumes obligation update forwardlooking statements result new information future events developments risks uncertainties include general industry conditions competition economic conditions interest rate currency exchange rate fluctuations technological advances new products patents attained competitors challenges inherent new product development including obtaining regulatory approvals challenges patents us foreign health care reforms governmental laws regulations trends toward health care cost containment increased scrutiny health care industry government agencies product efficacy safety concerns resulting product recalls regulatory action company 's report year ended december contains exhibit discussion additional factors could cause actual results differ expectations company notes factors permitted private securities litigation reform act consolidated balance sheets johnson johnson subsidiaries december december dollars millions except share per share data note table caption c c assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes deferred taxes income note prepaid expenses receivables total current assets marketable securities noncurrent notes property plant equipment net notes intangible assets net notes deferred taxes income note assets note total assets liabilities shareholders ' equity current liabilities loans notes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued salaries wages commissions accrued taxes income total current liabilities longterm debt note deferred tax liability note employee related obligations notes liabilities shareholders ' equity preferred stock without par value authorized unissued shares common stock par value per share note authorized shares issued shares note receivable employee stock ownership plan note accumulated comprehensive income note retained earnings less common stock held treasury cost note total shareholders ' equity total liabilities shareholders ' equity table see notes consolidated financial statements consolidated statements earnings johnson johnson subsidiaries dollars millions except per share figures note table caption c c c sales customers cost products sold gross profit selling marketing administrative expenses research expense purchased inprocess research development note interest income interest expense net portion capitalized note income expense net earnings provision taxes income provision taxes income note net earnings basic net earnings per share notes diluted net earnings per share notes table see notes consolidated financial statements consolidated statements equity johnson johnson subsidiaries dollars millions note table caption note rec employee compre stock owner hensive retained ship plan total income earnings esop c c c c bal dec net earnings cash dividends paid employee stock compensation stock option plans conver subordinated debentures repurchase common stock business combinations comprehensive income net tax curncy translation adj unrealized gains securities gains derivatives hedges reclassification adj total comprehensive income note receivable esop bal dec net earnings cash dividends paid employee stock compensation stock option plans conver subordinated debentures repurchase common stock comprehensive income net tax curncy translation adj unrealized losses securities pension liability adj losses derivatives hedges reclassification adj total comprehensive income note receivable esop bal dec net earnings cash dividends paid employee stock compensation stock option plans conver subordinated debentures repurchase common stock business combinations comprehensive income net tax curncy translation adj unrealized gains securities pension liab adj losses derivatives hedges reclassification adj total comprehensive income note receivable esop bal dec table see notes consolidated financial statements table caption accumul common compre stock treasury hensive issued stock income amount amount c c c bal dec net earnings cash dividends paid employee stock compensation stock option plans conversion subordinated debentures repurchase common stock business combinations comprehensive income net tax currency translation adj unrealized gains securities gains derivatives hedges reclassification adj total comprehensive income note receivable esop bal dec net earnings cash dividends paid employee stock compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adj unrealized losses securities pension liability adj losses derivatives hedges reclassification adj total comprehensive income note receivable esop bal dec net earnings cash dividends paid employee stock compensation stock option plans conversion subordinated debentures repurchase common stock business combinations comprehensive income net tax currency translation adj unrealized gains securities pension liability adj losses derivatives hedges reclassification adj total comprehensive income note receivable esop bal dec table see notes consolidated financial statements consolidated statements cash flows johnson johnson subsidiaries dollars millions note table caption c c c cash flows operating activities net earnings adjustments reconcile net earnings cash flows depreciation amortization property intangibles purchased inprocess research development deferred tax provision accounts receivable reserves changes assets liabilities net effects acquisition businesses increase accounts receivable decrease increase inventories increase accounts payable accrued liabilities increase current noncurrent assets increase current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assets acquisition businesses net cash acquired note purchases investments sales investments net cash used investing activities cash flows financing activities dividends shareholders repurchase common stock proceeds short term debt retirement short term debt proceeds long term debt retirement long term debt proceeds exercise stock options net cash used financing activities effect exchange rate changes cash cash equivalents increasedecrease cash cash equivalents cash cash equivalents beginning year note cash cash equivalents end year note supplemental cash flow data cash paid year interest income taxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds conversion debt acquisition businesses fair value assets acquired fair value liabilities assumed treasury stock issued fair value net cash paid acquisitions tablesee notes consolidated financial statements notes consolidated financial statements summary significant accounting principles principles consolidation financial statements include accounts johnson johnson subsidiaries intercompany accounts transactions eliminated new accounting pronouncements june financial accounting standards board fasb issued statement financial accounting standard sfas accounting asset retirement obligations company adopted standard material impact company 's results operations cash flows financial position june fasb issued sfas accounting costs associated exit disposal activities effective exit disposal activities initiated december company 's adoption sfas material effect company 's results operations cash flows financial position november fasb issued fasb interpretation fin guarantor 's accounting disclosure requirements guarantees including indirect guarantees indebtedness others interpretation fasb statements rescission fasb interpretation fin clarifies requirements fasb statement accounting contingencies relating guarantor 's accounting disclosure issuance certain types guarantees disclosure requirements fin effective financial statements interim annual periods end december provisions initial recognition measurement effective prospective basis guarantees issued modified december irrespective guarantor 's yearend fin requires upon issuance guarantee entity must recognize liability fair value obligation assumes guarantee company 's adoption fin material effect company 's results operations cash flows financial position january fasb issued fin consolidation variable interest entities interpretation arb december issued revised fin r consolidation variable interest entities interpretation arb address consolidation variable interest entities fin expanded criteria consideration determining whether variable interest entity consolidated business entity requires existing unconsolidated variable interest entities include limited special purpose entities spes consolidated primary beneficiaries entities effectively disperse risks among parties involved interpretation immediately applicable variable interest entities created january adoption portion fin material effect company 's results operation cash flows financial position fin applicable variable interest entities enterprise holds variable interest acquired february company various investments arrangements may may considered variable interests adoption fin anticipated material effect results operations cash flows financial position company april fasb issued sfas amendment statement derivative instruments hedging activities effective contracts entered modified june statement amends clarifies financial accounting reporting derivative instruments including certain derivative instruments embedded contracts hedging activities company 's adoption sfas material effect company 's results operations cash flows financial position may fasb issued sfas accounting certain financial instruments characteristics liabilities equity effective financial instruments entered modified may statement establishes standards issuer classifies measures certain financial instruments characteristics liabilities equity company 's adoption sfas material effect company 's results operations cash flows financial positionin december fasb issued sfas revised employers ' disclosures pensions postretirement benefits amendment fasb statement effective fourth quarter statement revises employers ' disclosures pension plans postretirement benefit plans disclosures included note december fasb issued fasb staff position fsp fas accounting disclosure requirements related medicare prescription drug improvement modernization act effective interim annual financial statements fiscal years ending december company elected defer adoption fsp fas allowed standard company 's adoption fsp fas expected material effect company 's results operations cash flows financial position cash equivalents company considers securities maturities three months less purchased cash equivalents investments shortterm marketable securities carried cost approximates fair value longterm debt securities company ability intent hold maturity carried amortized cost also approximates fair value investments classified availableforsale carried estimated fair value unrealized gains losses recorded component accumulated comprehensive income management determines appropriate classification investment debt equity securities time purchase reevaluates determination balance sheet date company periodically reviews investments nonmarketable equity securities impairment adjusts investments fair value decline market value deemed temporary property plant equipment depreciation property plant equipment stated cost company utilizes straightline method depreciation estimated useful lives assets table c building building equipment years land leasehold improvements years machinery equipment years table company capitalizes certain computer software development costs included machinery equipment incurred connection developing obtaining computer software internal use capitalized software costs amortized estimated useful lives software generally range years company reviews longlived assets assess recoverability using undiscounted cash flows necessary charges impairments longlived assets recorded amount present value future cash flows less carrying value assets revenue recognition company recognizes revenue product sales goods shipped delivered depending title risk passes customer provisions certain rebates sales incentives trade promotions product returns discounts customers provided reductions determining sales period related sales recorded company also recognizes service revenue received copromotion certain products sales incentives trade promotional allowances company adopted emerging issues task force eitf issue accounting consideration given vendor customer reseller vendor 's products effective december sales reduced million cost products sold increased million shipping handling shipping handling costs incurred million million million respectively included selling marketing administrative expense amount revenue received shipping handling less sales customers periods presented inventories inventories stated lower cost market determined firstin firstout method intangible assets accordance sfas amortization recorded goodwill andor intangible assets deemed indefinite lives acquisitions completed june effective beginning fiscal year accordance sfas company discontinued amortization relating existing goodwill indefinite lived intangible assets sfas effective effect would reduce amortization expense million tax intangible assets finite useful lives continue amortized useful lives sfas requires goodwill nonamortizable intangible assets assessed annually impairment company completed annual impairment test fiscal fourth quarter impairment determined future impairment tests performed fiscal fourth quarter annually financial instruments company follows provisions sfas accounting derivative instruments hedging activities amended sfas accounting certain derivative instruments certain hedging activities amendment fasb statement collectively referred sfas sfas requires derivative instruments recorded balance sheet fair value changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction depending type hedge transaction company uses forward exchange contracts manage exposure variability cash flows primarily related foreign exchange rate changes future intercompany product third party purchases raw materials denominated foreign currency company also uses currency swaps manage currency risk primarily related borrowings types derivatives designated cash flow hedges additionally company uses forward exchange contracts offset exposure certain foreign currency assets liabilities forward exchange contracts designated hedges therefore changes fair values derivatives recognized earnings thereby offsetting current earnings effect related foreign currency assets liabilities designation cash flow hedge made date entering derivative contract inception derivatives expected highly effective changes fair value derivative designated cash flow hedge highly effective recorded accumulated comprehensive income underlying transaction affects earnings reclassified earnings account hedged transaction fair value forward exchange contract represents present value change forward exchange rates times notional amount derivative fair value currency swap contract determined discounting present future cash flows currencies exchanged interest rates prevailing market periods currency exchanges due expressing result us dollars current spot foreign currency exchange rate ongoing basis company assesses whether derivative continues highly effective offsetting changes cash flows hedged items derivative longer expected highly effective hedge accounting discontinued hedge ineffectiveness included current period earnings company documents relationships hedged items derivatives overall risk management strategy includes reasons undertaking hedge transactions entering derivatives objectives strategy minimize foreign currency exposure 's impact company 's financialperformance protect company 's cash flow adverse movements foreign exchange rates ensure appropriateness financial instruments manage enterprise risk associated financial institutions product liability accruals product liability claims recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically additional information becomes available receivables insurance recoveries related product liability related claims recorded undiscounted basis probable recovery realized research development research development expenses expensed incurred upfront milestone payments made third parties connection research development collaborations expensed incurred point regulatory approval payments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized payments included intangibles net accumulated amortization advertising costs associated advertising expensed year incurred included selling marketing administrative expenses advertising expenses worldwide comprised television radio print media internet advertising billion billion billion income taxes company intends continue reinvest undistributed international earnings expand international operations therefore us tax expense recorded cover repatriation undistributed earnings december december cumulative amount undistributed international earnings approximately billion billion respectively deferred income taxes recognized tax consequences temporary differences applying enacted statutory tax rates applicable future years differences financial reporting tax basis existing assets liabilities net earnings per share basic earnings per share computed dividing net income available common shareholders weighted average number common shares outstanding period diluted earnings per share reflects potential dilution could occur securities contracts issue common stock exercised converted common stock stock options december company stockbased employee compensation plans described note company accounts plans recognition measurement principles accounting principle board opinion accounting stock issued employees apb related interpretations compensation costs recorded net income stock options options granted plans exercise price equal market value underlying common stock date grant required sfas accounting stockbased compensation transition disclosure amendment fasb statement following table shows estimated effect net income earnings per share company applied fair value recognition provision sfas accounting stockbased compensation stockbased employee compensation table caption dollars millions except per share data c c c net income reported less compensation expense pro forma earnings per share basic reported pro forma diluted reported pro forma table determined fair value based method awards net tax use estimates preparation consolidated financial statements conformity accounting principles generally accepted us requires management make estimates assumptions affect amounts reported actual results may may differ estimates annual closing date company follows concept fiscal year ends sunday nearest end month december normally fiscal year consists weeks every five six years case fiscal year consists weeks reclassification certain prior year amounts reclassified conform current year presentation stock split april board directors declared stock split shareholders record close business may issued one additional share johnson johnson common stock june share held record date shares per share data periods presented financial statements adjusted reflect stock split inventories end inventories comprised table caption dollars millions c c raw materials supplies goods process finished goods table property plant equipment end property plant equipment cost accumulated depreciation table caption dollars millions c c land land improvements buildings building equipment machinery equipment construction progress less accumulated depreciation table company capitalizes interest expense part cost construction facilities equipment interest expense capitalized million million million respectively depreciation expense including amortization capitalized interest billion billion billionrespectively upon retirement disposal fixed assets cost related amount accumulated depreciation amortization eliminated asset accumulated depreciation accounts respectively difference net asset value proceeds adjusted earnings rental expense lease commitments rentals space vehicles manufacturing equipment office data processing equipment operating leases approximately million million million approximate minimum rental payments required operating leases initial remaining noncancelable lease terms excess one year december table caption dollars millions total c c c c c c c table commitments capital leases significant employee related obligations end employee related obligations table caption dollars millions c c pension benefits postretirement benefits postemployment benefits deferred compensation current benefits payable employee related obligations table prepaid employee related obligations million million respectively included assets consolidated balance sheet borrowings components longterm debt follows table caption eff eff dollars millions rate rate c c c c zero coupon convertible subordinated debentures due debentures due debentures due debentures due notes due debentures due eurodollar notes due notes due convertible subordinated notes due notes due zero coupon convertible subordinated debentures due industrial revenue bonds less current portion table weighted average effective rate represents us dollar notes due issued japanese subsidiary converted fixed rate yen note via currency swap company access substantial sources funds numerous banks worldwide total unused credit available company approximates billion including billion credit commitments billion uncommitted lines various banks worldwide expire interest charged borrowings credit line agreements based either bids provided banks prime rate london interbank offered rates libor plus applicable margins commitment fees agreements material yearend company billion remaining shelf registration may company issued total billion bonds shelf million debentures due may million debentures due may december company filed new shelf registration securities exchange commission combination million remaining prior shelf registration may issue billion debt securities warrants purchase debt securities new shelf registration became effective january long term debt includes three convertible subordinated debentures two issued alza corporation one scios inc prior companies becoming wholly owned subsidiaries johnson johnson august scios inc issued private offering million convertible subordinated notes due interest payable semiannually february august notes convertible option holder time prior redemption repurchase maturity conversion price following acquisition johnson johnson april principal amount notes became convertible right receive cash without interest semiannual interest remains payable conversion repurchase maturity december book value notes approximates fair value july alza completed private offering zero coupon convertible subordinated debentures issued price per principal amount maturity december outstanding debentures total principal amount maturity billion yield maturity per annum computed semiannual bond equivalent basis periodic interest payments terms debentures holders entitled convert debentures approximately million shares johnson johnson stock price per share approximately shares issued december due voluntary conversions note holders option holder debentures may repurchased company july purchase price equal issue price plus accreted original issue discount purchase date company option may elect deliver either johnson johnson common stock cash combination stock cash event repurchase debentures company option may also redeem debentures july issue price plus accreted original issue discount december december fair value based quoted market value debentures million million respectively alza issued zero coupon convertible subordinated debentures price per principal amount maturity december outstanding debentures total principal amount maturity million yield maturity per annum computed semiannual bond equivalent basis periodic interest payments terms debentures note holders entitled convert theirdebentures approximately million shares johnson johnson stock price per share approximately million shares johnson johnson stock issued december due voluntary conversions debenture holders option holder debentures purchased company july july purchase price equal issue price plus accreted original issue discount purchase date company option may elect deliver either common stock cash event conversion purchase debentures company option may also redeem debentures cash july redemption price equal issue price plus accreted original issue discount december december fair value based quoted market value debentures million million respectively shortterm borrowings current portion longterm debt amounted billion end borrowings comprised million commercial paper million eurodollar notes maturing million local borrowings principally international subsidiaries aggregate maturities longterm obligations commencing table caption dollars millions c c c c c c table intangible assets end gross net amounts intangible assets table caption dollars millions c c goodwill gross less accumulated amortization goodwill net trademarks nonamortizable gross less accumulated amortization trademarks nonamortizable net patents trademarks gross less accumulated amortization patents trademarks net intangibles gross less accumulated amortization intangibles net total intangible assets gross less accumulated amortization total intangible assets net table goodwill december allocated segments business follows table caption med dev dollars millions consumer pharm diag total c c c c goodwill net accumulated amortization december acquisitions translation goodwill december table weighted average amortization periods patents trademarks otherintangible assets years years respectively amortization expense amortizable intangible assets fiscal year ended december million tax estimated amortization expense five succeeding years approximates million tax per year income taxes provision taxes income consists table caption dollars millions c c c currently payable us taxes international taxes deferred us taxes international taxes table comparison income tax expense federal statutory rate company 's effective tax rate follows table caption dollars millions c c c us international earnings taxes income statutory taxes tax rates statutory puerto rico ireland operations research tax credits us state local international subsidiaries excluding ireland iprd effective tax rate table company subsidiaries operating puerto rico various tax incentive grants addition company subsidiaries manufacturing ireland incentive tax rate temporary differences carry forwards follows table caption deferred tax deferred tax dollars millions asset liability asset liability c c c c employee related obligations depreciation nondeductible intangibles international rd capitalized tax reserves liabilities income reported tax purposes miscellaneous international capitalized intangible miscellaneous us total deferred income taxes table difference net deferred tax income per balance sheet net deferred tax included taxes income balance sheet international currency translation translation subsidiaries operating nonus dollar currencies company determined local currencies international subsidiaries functional currencies except highly inflationary economies defined compound cumulative rates inflation past three years consolidating international subsidiaries balance sheet currency effects recorded component accumulated comprehensive income equity account includes results translating balance sheet assets liabilities current exchange rates except located highly inflationary economies reflected operating results analysis changes foreign currency translation adjustments included note net currency transaction translation gains losses included expense tax losses million million million respectively common stock stock option plans stock compensation agreements december company stockbased compensation plans stock option plan company may grant options employees issued shares company 's common stock plus number shares available previous year issued well shares issued plan expired terminated without exercised shares outstanding contracts company 's stock option plans nonemployee director 's plan mitek cordis biosense gynecare centocor innovasive devices alza inverness scios stock option plans options granted plans except stock option plan scios stock option plan preacquisition stock options expire years date granted vest service periods range one five years options granted current market price date grant shares available stock option plan future grants based issued shares year million shares could granted year years addition available shares described shares available future grants plan million end summary status company 's stock option plans december december december changes years ending dates presented table caption weighted options average shares thousands outstanding exercise price c c balance december options granted options exercised options canceledforfeited balance december options granted options exercised options canceledforfeited balance december options granted options exercised options canceledforfeited balance december table includes options issued replace inverness options outstanding orgranted prior acquisition includes options issued replace scios options outstanding granted prior acquisition year ended december change timing granting stock compensation options employees december february change enacted results finalized order align compensation performance timing grants followed prospectively average fair value options granted fair value estimated using blackscholes option pricing model based weighted average assumptions table caption c c c riskfree rate volatility expected life yrs yrs yrs dividend yield table following table summarizes stock options outstanding exercisable december shares thousands table caption outstanding exercisable average average exercise average exercise exercise price range options lifea price options price c c c c c table average contractual life remaining years stock options exercisable december december options average price options average exercise price respectively segments business geographic areas accumulated comprehensive income components comprehensive incomeloss consist following dollars millions table caption total unrld gains accum gains pens losses cur losses liab deriv comp trans sec adj hedg incloss c c c c c dec net changes dec changes net change dueto hedging transactions net amount reclassed net earnings net changes dec changes net change due hedging transactions net amount reclassed net earnings net changes dec table total comprehensive income includes reclassification adjustment losses million realized sale equity securities associated tax benefit million total comprehensive income includes reclassification adjustment gains million realized sale equity securities associated tax expense million total comprehensive income included reclassification adjustment gains million realized sale equity securities associated tax expense million tax effect unrealized gainslosses equity securities expense million benefit million expense million tax effect gainslosses derivatives hedges benefits million million respectively expense million see note additional information relating derivatives hedging currency translation adjustments currently adjusted income taxes relate permanent investments international subsidiaries pensions benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide company also provides postretirement benefits primarily health care us retired employees dependents many international employees covered governmentsponsored programs cost company significant retirement plan benefits primarily based employee 's compensation last three five years retirement number years service international subsidiaries plans funds deposited trustees annuities purchased group contracts reserves provided company fund retiree health care benefits advance right modify plans future december sfas revised employers ' disclosures pensions postretirement benefits issued amends disclosure requirements pensions postretirement benefits revised statement addresses disclosures address liability measurement expense recognition company uses date consolidated financial statements december december respectively measurement date us international retirement benefit plans net periodic benefit costs company 's defined benefit retirement plans benefit plans include following components table caption retirement plans benefit plans dollars millions c c c c c c service cost interest cost expected return plan assets amortization prior service cost amortization net transition asset recognized actuarial lossesgains curtailments settlements special termination benefits net periodic benefit cost table net periodic cost attributable us retirement plans million million million company offered voluntary retirement program enhanced benefits called retirement enhancement program rep eligible us regular fulltime employees attained age least years pension credited service june program enhancements include elimination early retirement reduction pension benefit purposes normally per year prior age special termination benefit one week pay per year credited service program resulted increase us pension expense million reflect value retirement enhancement weightedaverage assumptions following table represent rates used develop actuarial present value projected benefit obligation year listed also net periodic benefit cost following year table caption retirement plans us benefit plans c c c c discount rate expected longterm rate return plan assets rate increase compensation levels international benefit plans discount rate expected longterm rate return plan assets rate increase compensation levels table table caption benefit plans us benefit plans c c c c discount rate expected longterm rate return plan assets rate increase compensation levels international benefit plans discount rate expected longterm rate return plan assets rate increase compensation levels table expected longterm rate return plan assets assumptions determined using building block approach considering historical averages realreturns asset class certain countries historical returns meaningful consideration given local market expectations longterm returns following table displays assumed health care trend rates individuals table caption worldwide benefit plans c c health care trend rate assumed next year rate cost trend rate assumed decline ultimate trend year rate reaches ultimate trend rate table onepercentagepoint change assumed health care cost trend rates would following effect table caption onepercentage onepercentage dollars millions point increase point decrease c c worldwide benefit plans total interest service cost postretirement benefit obligation table following table sets forth information related benefit obligation fair value plan assets yearend company 's defined benefit retirement plans postretirement plans table caption retirement plans benefit plans dollars millions change benefit obligation c c c c projected benefit obligation beginning year service cost interest cost plan participant contributions amendments actuarial losses divestitures acquisitions curtailments settlements benefits paid plan effect exchange rates projected benefit obligation end year change plan assets plan assets fair value beginning year actual return plan assets company contributions plan participant contrib divestitures benefits paid plan assets effect exchange rates plan assets fair value end year table strategic asset allocations determined country based nature liabilities considering demographic composition plan participants average age years service active versus retiree status company 's plans considered nonmature plans longterm strategic asset allocations consistent types plans emphasis placed diversifying equities broad basis combined currency matching fixed income assets derivatives used primarily hedge currency exposurethe company expected fund us retirement plans order meet minimum statutory funding requirements international plans funded accordance local regulations additional discretionary contributions made deemed appropriate meet longterm obligations plans certain countries united states funding pension plans common practice funding provides economic benefit consequently company several pension plans funded company expects contribute million benefit plans meet current year medical claim obligations following table displays projected future contributions company 's us unfunded retirement plans table caption dollars millions c c c c c c us retirement plans unfunded retirement plans table company 's retirement plan asset allocation end target allocations follows table caption percent target plan assets allocation dollars millions c c c us retirement plans equity securities debt securities total plan assets international retirement plans equity securities debt securities real estate total plan assets table company 's benefit plans unfunded except us life insurance contract assets million million december december respectively fair value johnson johnson common stock directly held plan assets million total plan assets december million total plan assets december amounts recognized company 's balance sheet consist following table caption retirement plans benefit plans dollars millions c c c c plan assets fair value projected benefit obligation funded status unrecognized actuarial losses unrecognized prior service cost unrecognized nettransition asset total recognized consolidated balance sheet table table caption retirement plans benefit plans dollars millions c c c c book reserves prepaid benefits intangible assets accumulated comprehensive income total recognized consolidated balance sheet table accumulated benefit obligation us international defined benefit retirement plans billion billion december december respectively minimum pension liability adjustment required actuarial present value accumulated benefits obligation abo exceeds fair value plan assets accrued pension liabilities minimum pension liabilities intangible assets accumulated comprehensive income million million respectively relate primarily plans outside us increase minimum liability included comprehensive income million million respectively plans accumulated benefit obligations excess plan assets consist following table caption retirement plans dollars millions c c accumulated benefit obligation projected benefit obligation plan assets fair value table december medicare prescription drug improvement modernization act enacted introduces prescription drug benefit medicare well subsidy sponsors retiree health care benefit plans company elected defer recognition act time authoritative guidance issued measures accumulated postretirement benefit obligation net periodic postretirement benefit cost company 's financial statements reflect effect act marketable securities table caption december un un real real est net ized ized fair cost gains losses value c c c c money market funds commercial paper time deposits government securities obligations bank notes corporate debt securities total current marketable securities government securities bank notes corporate debt securities investments held trust total noncurrent marketable securities table table caption december un un real real est net ized ized fair cost gains losses value c c c c money market funds commercial paper time deposits government securities obligations bank notes corporate debt securities total current marketable securities government securities bank notes corporate debt securities investments held trust total noncurrent marketable securities table current marketable securities include billion billion classified cash equivalents balance sheet december december respectively financial instruments company follows provisions sfas requiring derivative instruments recorded balance sheet fair value december balance deferred net losses derivatives included accumulated comprehensive income million aftertax additional information see note company expects substantially amount reclassified earnings next months result transactions expected occur period amount ultimately realized earnings differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity derivative transactions third parties cause amount accumulated comprehensive income affect net earnings maximum length time company hedging months year ended december net impact hedges ' ineffectiveness company 's financial statements insignificant year ended december company recorded net gain million tax income expense net category consolidated statement earnings representing impact discontinuance cash flow hedges probable originally forecasted transactions occur end originally specified time period refer note disclosures movements accumulated comprehensive income concentration credit risk company invests excess cash deposits major banks throughout world high quality money market instruments refer note additional information company policy making investments commercial institutions least equivalent credit rating investments generally mature within six months company incurred related losses savings plan company voluntary k savings plans designed enhance existing retirement programs covering eligible employees company matches percentage employee 's contributions consistent provisions plan heshe eligible us salaried plan onethird company match paid company stock employee stock ownership plan esop unless employee chooses redirect investment establish esop company loaned million esop trust purchase shares company stock open market exchange company received note balance recorded reduction shareholders ' equity total company contributions plans million million million mergers acquisitions divestitures certain businesses acquired billion cash million liabilities assumed acquisitions accounted purchase method accordingly results operations included accompanying consolidated financial statements respective dates acquisition acquisitions included link spine group inc privately owned corporation exclusive worldwide rights charite artificial disc scios inc biopharmaceutical company marketed product cardiovascular disease research projects focused autoimmune diseases dimensional pharmaceuticals inc company technology platform focused discovery development therapeutic small molecules orapharma inc specialty pharmaceutical company focused development commercialization unique oral therapeutics certain assets orquest inc privately held biotechnology company focused developing biologicallybased implants orthopaedics spine surgery excess purchase price estimated fair value tangible assets acquired amounted billion allocated identifiable intangibles goodwill approximately million identified value inprocess research development iprd primarily associated acquisition link spine group inc scios inc iprd charge related link spine acquisition million associated charite artificial disc charite artificial disc marketed countries outside us premarket approval application filed us food drug administration february value iprd calculated assistance third party appraiser using cash flow projections discounted risk inherent projects probability success factor used reflect inherent clinical regulatory risk discount rate preliminary basis purchase price link spine acquisition allocated tangible identifiable intangible assets acquired liabilities assumed based estimated fair values acquisition date excess purchase price fair values assets liabilities acquired approximately million allocated goodwill company expects substantially amount allocated goodwill deductible tax purposes iprd charge related scios million largely associated p kinase inhibitor program value iprd calculated assistance third party appraiser using cash flow projections discounted risk inherent projects using probability success factor discount rate preliminary basis purchase price scios inc acquisition allocated tangible andidentifiable intangible assets acquired liabilities assumed based estimated fair values acquisition date identifiable intangible assets included patents trademarks valued approximately billion excess purchase price fair values assets liabilities acquired approximately million allocated goodwill company expects substantially amount allocated goodwill deductible tax purposes remaining iprd associated orquest inc dimensional pharmaceuticals inc charges million million respectively cases value iprd calculated assistance third party appraiser certain businesses acquired million cash liabilities assumed million acquisitions accounted purchase method accordingly results operations included accompanying consolidated financial statements respective dates acquisition acquisitions included tibotecvirco nv privatelyheld biopharmaceutical company focused developing antiviral treatments micro typing systems inc manufacturer reagents supplier distributed instruments known idmicro typing system obtech medical ag privatelyheld company markets adjustable gastric band treatment morbid obesity excess purchase price estimated fair value tangible assets acquired entities amounted million allocated identifiable intangibles goodwill approximately million identified value iprd associated tibotecvirco nv obtech medical ag acquisitions iprd charge related tibotecvirco nv million associated two early stage hiv compounds value iprd calculated assistance third party appraiser using cash flow projections discounted risk inherent projects using probability success factors ranging discount rate iprd charge related obtech medical ag million associated development current swedish adjustable gastric band sagb use united states well development next generation technology platform value iprd calculated assistance third party appraiser using cash flow projections discounted risk inherent projects using probability success factor discount rate supplemental pro forma information per sfas business combinations sfas goodwill intangible assets provided impact aforementioned acquisitions material effect company 's results operations cash flows financial position june johnson johnson alza corporation alza completed merger two companies transaction accounted poolingofinterests alza approximately million shares outstanding million fully diluted basis exchanged approximately million shares johnson johnson common stock diluted basis adjusted stock options convertible debt total number johnson johnson shares issued approximately million holders alza common stock received share johnson johnson common stock valued per share alza researchbased pharmaceutical company leading drug delivery technologies company applies delivery technologies develop pharmaceutical products enhanced therapeutic value johnson johnson affiliate portfolios many world 's leading pharmaceutical companies certain businesses acquired billion billion cash liabilities assumed million shares company 's common stock issued treasury valued billion acquisitions accounted purchase method accordingly results operations included accompanying consolidated financial statements respective dates acquisition acquisitions included inverness medical technology inc supplier lifescan 's electrochemical products blood glucose monitoring following spinoff nondiabetes businesses heartport inc company thatdevelops manufactures products less invasive open chest minimally invasive heart operations including stopped heart beating heart procedures teramed corporation earlystage medical device company developing endovascular stentgraft systems minimally invasive treatment abdominal aortic aneurysms peripheral occlusive disease babycenter llc internet content commerce company devoted supporting community expectant new mothers viactiv product line chewable calcium supplement mead johnson nutritionals division bristolmyers squibb inverness medical technology acquired enhance control primary supplier lifescan blood glucose monitoring products allow achievement operational synergies acquisition also provides key technology development future products approximately million identified value iprd associated inverness medical technology teramed corporation acquisitions iprd charge primarily related inverness projects minimally invasive testing continuous monitoring insulin delivery value iprd calculated assistance third party appraiser using cash flow projections discounted risk inherent projects using probability success factors ranging discount rate used divestitures material effect company 's results operations cash flows financial position legal proceedings product liability litigation company involved numerous product liability cases united states many concern adverse reactions drugs medical devices damages claimed substantial company confident adequacy warnings instructions use accompany products feasible predict ultimate outcome litigation however company believes liability results cases substantially covered reserves established selfinsurance program commercially available excess liability insurance one group cases company concerns janssen pharmaceutica product propulsid withdrawn general sale restricted limited use wake publicity events numerous lawsuits filed janssen wholly owned subsidiary company company regarding propulsid state federal courts across country approximately cases currently pending including claims approximately plaintiffs active cases individuals alleged died use propulsid actions seek substantial compensatory punitive damages accuse janssen company inadequately testing warning drug 's side effects promoting offlabel use promotion addition janssen company entered agreements various plaintiffs ' counsel halting running statutes limitations respect potential claims tolling agreements significant number individuals attorneys evaluate whether sue janssen company behalf september first ten plaintiffs rankin case comprises claims propulsid plaintiffs went trial state court claiborne county mississippi jury returned compensatory damage verdicts plaintiff amount million total million trial judge thereafter dismissed claims punitive damages march trial judge reduced verdicts total million denied motions janssen company new trial janssen company believe verdicts even reduced insupportable appealed view janssen company proof trial demonstrated none plaintiffs injured propulsid basis liability existed april state court judge new jersey denied plaintiffs ' motion certify national class propulsid users purposes medical monitoring refund costs purchasing propulsid effort appeal ruling denied june federal judge presiding propulsid multidistrict litigation new orleans louisiana similarly denied plaintiffs ' motion certify national class propulsid users plaintiffs multidistrict litigation said preserving right appeal ruling complaints filed janssen company include class action allegations could basis future attempts classes certified february janssen announced reached agreement principle plaintiffs steering committee psc propulsid federal multidistrict litigation mdl resolve federal lawsuits related propulsid approximately individuals included federal mdlof approximately alleged died use drug agreement becomes effective percent death claims percent remainder agree terms settlement addition individuals filed lawsuits whose claims subject tolling agreements suspending running statutes limitations claims must also agree participate settlement become effective agreeing participate settlement submit medical records independent panel physicians determine whether claimed injuries caused propulsid otherwise meet standards compensation standards met courtappointed special master determine compensatory damages janssen pay compensation minimum million maximum million depending upon number plaintiffs enroll program janssen also establish administrative fund exceed million pay legal fees psc million subject court approval respect various propulsid actions janssen company dispute claims lawsuits vigorously defending except judgment settlement appropriate janssen company believe adequate selfinsurance reserves commercially available excess insurance respect cases communications company excess insurance carriers raised certain defenses liability policies date declined reimburse janssen company propulsidrelated costs despite demand payment however opinion company defenses pro forma lack substance carriers honor obligations policies either voluntarily litigation company recently commenced arbitration allianz underwriters insurance company issued first layer applicable excess insurance coverage obtain reimbursement propulsidrelated costs company 's ethicon inc subsidiary last several years number claims lawsuits filed relating vicryl sutures actions allege sterility vicryl sutures compromised inadequacies ethicon 's systems controls causing patients exposed sutures incur infections would otherwise occurred ethicon several occasions recalled batches vicryl sutures light questions raised sterility believe contamination suture products fact occurred november trial judge west virginia certified class treatment west virginia residents vicryl sutures implanted class ii surgeries may december certification subject later challenge following conclusion discovery trial date set matter ethicon intends continue vigorously contesting liability affirmative stent patent litigation patent infringement actions tried delaware federal court late cordis corporation subsidiary johnson johnson obtained verdicts infringement patent validity damage awards boston scientific corporation medtronic ave inc based number cordis vascular stent patents december jury damage action boston scientific returned verdict million december jury medtronic ave action returned verdict million sums represent lost profit reasonable royalty damages compensate cordis infringement include pre post judgment interest february hearing held claims boston scientific medtronic ave patents issue unenforceable owing alleged inequitable conduct patent office march may district judge issued post trial rulings confirmed validity enforceability main cordis stent patent claims found certain cordis patents unenforceable district judge granted boston scientific new trial liability damages vacated verdict medtronic ave legal grounds august court appeals federal circuit found trial judge erred vacating verdict medtronic ave remanded case trial judge proceedings medtronic ave 's motion reconsideration panel reconsideration full court denied october request stay return mandate trial court pending filing request writ certiorari united states supreme court denied october medtronic ave filed petition writ certiorari united states supreme court january cordis filed motions trial court october reinstate verdicts medtronic ave boston scientific award interest enter injunctions stent products issue two cases gfx andmicrostent stents medtronic ave nir stent boston scientific colorable variations thereof medtronic ave boston scientific resisting reinstatement verdicts likely attempt appeal court appeals federal circuit judgments entered january cordis filed additional patent infringement action boston scientific delaware federal court accusing express taxus stents infringing one cordis patents involved earlier actions boston scientific medtronic ave february cordis moved action preliminary injunction seeking bar introduction taxus stent based patent november district judge denied request preliminary injunction cordis filed appeal court appeals federal circuit decision federal circuit expected nd rd quarter cordis also pending delaware federal court another action medtronic ave accusing medtronic ave infringement stent products introduced medtronic ave subsequent gfx microstent products subject earlier action referenced early june arbitration panel chicago preliminary ruling found favor cordis arbitration acsguidant involving infringement acsguidant cordis stent patent august panel confirmed ruling rejecting challenge acsguidant terms earlier agreement cordis acsguidant arbitration panel 's ruling obligated acsguidant make payment million cordis made fiscal fourth quarter result resolving matter fiscal fourth quarter million recorded income expense approximately million tax relating past periods balance award million approximately million tax recognized income future periods estimated remaining life intellectual property additional royalties acsguidant 's continued use technology injunction involved patent litigation various johnson johnson operating companies products various johnson johnson operating companies subject various patent lawsuits could potentially affect ability operating companies sell products require payment past damages future royalties following patent lawsuits concern important products johnson johnson operating companies boston scientific medinol ltd v cordis corporation action filed delaware federal court december charged infringement bx velocity cordis stent products certain patents owned medinol licensed boston scientific case tried jury september resulted verdicts cordis noninfringement invalidity except respect minor stent product jury found infringement awarded damages million medinol filed appeal result affirmed court appeal federal circuit january medtronic ave v cordis corporation action filed april federal district court texas thereafter transferred federal district court delaware asserts certain patents owned medtronic ave cordis bx velocity stent also stent structure used cypher drugeluting product federal district court delaware recently reversed prior decision stay lawsuit pending outcome arbitration parties issue whether cordis licensed patents asserted medtronic ave boston scientific corporation bsc v cordis corporation action filed delaware federal court march asserts cypher drugeluting stent infringes several patents assigned boston scientific boston scientific seeks damages permanent injunction boston scientific corporation bsc v cordis corporation action filed delaware federal court december asserts cordis cypher drug eluting stent infringes several patents assigned bsc neorx pertaining pharmaceutical compounds use stents bsc seeking damages permanent injunction medinol ltd v cordis europe nv netherlands medinol ltd v cordis holding belgium bvba janssen pharmaceutica nv belgium july appeal court hague overturned lower court granted medinol israeli stent manufacturer preliminary injunction based patent infringement prohibiting cordis making selling bx velocity cypher stents netherlands injunction became effective august belgium medinol filed patent infringement suit based patent asserted netherlands moved preliminary injunction seeking prevent defendants making selling bx velocity cypher stents motion denied trial court november medinol appealed cordis currently uses janssen pharmaceutica facility belgium coat cypher stents sirolimus principally exus market rockey v cordis corporation action cordis heirs drrockey concerning patent licensed cordis shortly cordis acquired johnson johnson plaintiffs assert dr rockey 's patent expires february covers stent products ever marketed cordis seek royalty sales trial action pending federal court miami florida scheduled march february ascguidant cordis corporation entered strategic alliance copromotion drugeluting stents result agreement pending litigation companies settled respect matters johnson johnson operating company involved vigorously defending claims infringement disputing appropriate validity enforceability patent claims asserted litigation filers abbreviated new drug applications andas following lawsuits generic firms filed abbreviated new drug applications andas seeking market generic forms products sold various subsidiaries company prior expiration applicable patents covering products andas typically include allegations noninfringement invalidity unenforceability patents event subsidiary company involved successful actions firms involved introduce generic versions product issue resulting substantial market share revenue losses product company 's subsidiary orthomcneil pharmaceutical inc daiichi inc v mylan laboratories orthomcneil pharmaceutical inc daiichi inc v teva pharmaceutical matters first filed february federal court west virginia second june federal court new jersey concern efforts mylan teva invalidate establish noninfringement unenforceability patent covering levaquin levofloxacin tablets patent owned daiichi exclusively licensed orthomcneil first phase trial mylan case concluded december second phase concluded may trial date set teva matter orthomcneil pharmaceutical inc daiichi v bedford laboratories matter filed federal district court new jersey april involves effort bedford invalidate assert noninfringement unenforceability daiichi patent levaquin involved proceedings case however bedford challenging patent 's application products asserts equivalent levaquin injection premix injection vials rather tablets orthomcneil pharmaceutical inc daiichi v american pharmaceutical partners sicor pharmaceutical december orthomcneil pharmaceutical inc daiichi filed suits federal district court new jersey american pharmaceutical partners sicor pharmaceutical respect andas filed entities involving daiichi patent levaquin injection premix single use vials janssen pharmaceutica inc alza corporation v mylan laboratories action filed federal district court vermont january concerns mylan 's effort invalidate assert noninfringement unenforceability alza 's patent covering duragesic fentanyl transdermal system product trial concluded september posttrial briefing completed december mylan stated publicly intends launch generic duragesic july even loses case district court asserts janssen alza forfeited benefits fda grant pediatric exclusivity filing lawsuit late janssen alza vigorously dispute contention janssen pharmaceutica nv v eon labs manufacturing action filed federal court eastern district new york april concerns eon 's effort invalidate establish noninfringement janssen 's patent covering sporanox itraconozole trial date yet scheduled orthomcneil pharmaceutical inc v kali laboratories inc lawsuit filed federal court new jersey november concerns attempt kali invalidate establish noninfringement orthomcneil 's patent covering ultracet tramadolacetaminophen tablets trial date set case alza corporation v mylan laboratories action filed federal district court west virginia may concerns mylan 's effort invalidate assert noninfringement alza patent covering orthomcneil product ditropan xl oxybutynin chloride trial scheduled february case alza corporation v impax laboratories action filed federal court california september concerns impax 's effort invalidate assert noninfringement alza patent covering ditropan xl involved mylan case trial date set matter orthomcneil pharmaceutical inc v barr laboratories inc action filed federal district court new jersey october concerns effort barr laboratories assert noninfringement invalidity unenforceability orthomcneil 's patent ortho tricyclen lonorgestimateethinyl estradiol oral contraceptive product janssen pharmaceutica nv v mylan pharmaceuticals inc action filed federal district court new jersey december concerns mylan 's effort invalidate janssen patent covering risperdal risperidone tablets janssen pharmaceutica nv v dr reddy 's laboratories inc action filed federal district court new jersey concerns dr reddy 's efforts invalidate janssen patent covering risperdal tablets immediately preceding mylan case eisai inc v dr reddy 's laboratories inc action filed janssen 's us copromotion partner eisai inc federal court new york concerns dr reddy 's effort invalidate assert noninfringement eisai patent covering aciphex rabeprazole sodium tablets trial date set eisai inc v teva pharmaceuticals usa action also filed janssen 's us copromotion partner eisai inc concerns teva 's efforts invalidate assert noninfringement eisai patent involved immediately preceding dr reddy 's case trial date set matter eisai inc v mylan pharmaceuticals inc january janssen 's us copromotion partner eisai inc filed action federal district court new york mylan pharmaceuticals inc regarding mylan 's efforts invalidate assert noninfringement eisai patent covering aciphex tablets dr reddy 's teva cases trial date set janssen pharmaceutica inc party eisai actions respect matters johnson johnson operating company involved vigorously defending validity enforceability asserting infringement licensor 's patents average wholesale price awp litigation johnson johnson pharmaceutical operating companies along numerous pharmaceutical companies defendants series lawsuits state federal courts involving allegations pricing marketing certain pharmaceutical products amounted fraudulent otherwise actionable conduct among things companies allegedly reported inflated average wholesale price awp drugs issue cases federal actions state actions removed federal court consolidated pretrial purposes multidistrict litigation mdl federal court boston massachusetts plaintiffs cases include classes private persons entities paid portion purchase drugs issue based awp state government entities made medicaid payments drugs issue based awp ethicon endosurgery inc johnson johnson operating company markets endoscopic surgical instruments company named defendants north carolina state court class action lawsuit alleging awp inflation improper marketing activities tap pharmaceuticals ethicon endosurgery inc defendant based claims several former sales representatives alleged involved arbitrage tap drug allegation sales representatives persuaded certain physicians states drug 's price low purchase tap excess quantities drug resell states price higher ethicon endosurgery inc company deny liability claims made case vigorously defending trial judge recently certified national class purchasers tap product issue trial likely new york state attorney general 's office federal trade commission issued subpoenas january february seeking documents relating marketing sutures endoscopic instruments company 's ethicon inc ethicon endosurgery inc subsidiaries connecticut attorney general 's office also issued subpoena documents subpoenas focus bundling sutures endoscopic instruments contracts offered group purchasing organizations individual hospitals discounts predicated hospital achieving specified market share targets categories products operating companies involved responding subpoenas june company received request records information us house representatives ' committee energy commerce connection investigation pharmaceutical reimbursements rebates medicaid committee 's request focuses drug remicade infliximab marketed company 's centocor inc subsidiary july centocor received request voluntarily provide documents information criminal division us attorney 's office district new jersey connection investigation various centocor marketing practices company centocor responding requests documents information august securities exchange commission sec advised company informal investigation foreign corrupt practices act allegations payments polish governmental officials us pharmaceuticalcompanies november sec advised company investigation become formal issued subpoena information previously requested informal fashion plus background documents company operating units poland responding requests december company 's orthomcneil pharmaceutical unit received subpoena united states attorney 's office boston massachusetts seeking documents relating marketing including alleged offlabel market ing drug topamax topiramate approved antiepilepsy therapy orthomcneil cooperating responding subpoena january company 's janssen unit received subpoena office inspector general united states office personnel management seeking documents concerning payments physicians connection sales marketing clinical trials risperdal janssen cooperating responding subpoena company recorded million damages million legal fees costs connection arbitration proceeding filed involving company 's ortho biotech subsidiary amgen ortho biotech 's licensor us nondialysis rights procrit epoetin alfa amgen sought terminate ortho biotech 's us license rights collect substantial damages proceeding based alleged deliberate procrit sales ortho biotech early 's amgen 's reserved dialysis market october arbitrator issued decision rejecting amgen 's request terminate license finding material breach license however arbitrator found conduct ortho biotech early 's subsequently halted ortho biotech amounted nonmaterial breach license awarded amgen million damages company accrued third quarter january arbitrator ruled amgen prevailing party arbitration entitling award reasonable attorney 's fees costs company accrued million fourth quarter connection claim remand federal circuit court appeals january partial retrial commenced october concluded november boston massachusetts action amgen v transkaryotic therapies inc tkt aventis pharmaceutical inc matter patent infringement action brought amgen tkt developer geneactivated epo product aventis holds marketing rights tkt product asserting tkt 's product infringes various amgen patent claims tkt aventis dispute infringement seeking invalidate amgen patents asserted district court issued preliminary rulings upheld district court 's initial findings opinion district court expected second quarter proceedings appeal follow amgen patents issue case exclusively licensed ortho biotech inc johnson johnson operating company us nondialysis indications ortho biotech inc party action company also involved number patent trademark lawsuits incidental business ultimate legal financial liability company respect claims lawsuits proceedings referred estimated certainty however opinion management based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities already accrued company 's consolidated balance sheet expected material adverse effect company 's consolidated financial position although resolution reporting period one matters could significant impact company 's results operations cash flows period earnings per share following reconciliation basic net earnings per share diluted net earnings per share years ended december december december table caption shares millions c c c basic earnings per share average shares outstanding basic potential shares exercisable stock option plans less shares repurchased treasury stock method convertible debt shares adjusted average shares outstanding diluted diluted earnings per share table diluted earnings per share calculation includes dilution effect convertible debt decrease interest expense million million million tax years respectively diluted earnings per share excludes million shares underlying stock options million shares underlying stock options years exercise price options greater average market value resulting antidilutive effect diluted earnings per share capital treasury stock changes treasury stock table caption treasury stock dollars millions except number shares thousands shares amount c c balance december employee compensation stock option plans conversion subordinated debentures repurchase common stock business combinations balance december employee compensation stock option plans conversion subordinated debentures repurchase common stock balance december employee compensation stock option plans conversion subordinated debentures repurchase common stock balance december table shares common stock issued shares end selected quarterly financial data unaudited selected unaudited quarterly financial data years summarized dollars millions except per share data table caption first second third fourth qtr qtr qtr qtr c c c c segment sales customers consumer pharmaceutical med devices diagnostics total sales gross profit earnings provision taxes income net earnings basic net earnings per share diluted net earnings per share table dollars millions except per share datatable caption first second third fourth qtr qtr qtr qtr c c c c segment sales customers consumer pharmaceutical med devices diagnostics total sales gross profit earnings provision taxes income net earnings basic net earnings per share diluted net earnings per share table first quarter includes tax charge million inprocess research development iprd costs second quarter includes tax charge million iprd costs fourth quarter includes tax income million arbitration ruling stent patents cost retirement enhancement program million second quarter includes tax charge million iprd costs third quarter includes tax charge million amgen arbitration settlement fourth quarter includes tax charge million amgen arbitration settlement report independent auditors shareholders board directors johnson johnson opinion accompanying consolidated balance sheets related consolidated statements earnings consolidated statements equity consolidated statements cash flows present fairly material respects financial position johnson johnson subsidiaries december december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america financial statements responsibility company 's management responsibility express opinion financial statements based audits conducted audits statements accordance auditing standards generally accepted united states america require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion discussed note financial statements company adopted statement financial accounting standards goodwill intangible assets effective december pricewaterhousecoopers llp pricewaterhousecoopers llp new york new york january except fifth thirteenth paragraphs note dates february february respectively segments business johnson johnson subsidiaries table caption sales customers dollars millions c c c consumer united states international total pharmaceutical united states international total med devices diag united states international total worldwide total table table caption operating profit dollars millions c c c consumer pharmaceutical medical devices diagnostics segments total expenses allocated segments worldwide total table table caption identifiable assets dollars millions c c c consumer pharmaceutical medical devices diagnostics segments total general corporate worldwide total table table caption additions property plant equipment dollars millions c c c consumer pharmaceutical medical devices diagnostics segments total general corporate worldwide total table table caption depreciation amortization dollars millions c c c consumer pharmaceutical medical devices diagnostics segments total general corporate worldwide total table table caption sales customers dollars millions c c c united states europe western hemisphere excluding us asiapacific africa worldwide total table table caption longlived assets dollars millions c c c united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total table see management 's discussion analysis description segments company business export sales intersegment sales significant sales three distributors accounted sales concentrated pharmaceutical segment sales procriteprex accounted total company revenues respectively amounts allocated segments include interest incomeexpense minority interest general corporate income expense general corporate includes cash marketable securities includes million inprocess research development iprd pharmaceutical segment million iprd million arbitration ruling stent patents medical devices diagnostics segment includes million iprd million million costs related arbitration settlement procrit pharmaceutical segment million iprd medical devices diagnostics segment includes million alza merger costs pharmaceutical segment million iprd summary operations statistical data johnson johnson subsidiariesdollars millions except per share figures table caption c c c c c sales customers domestic sales customers international total sales cost products sold selling marketing admin expenses research expense purchased inprocess research develop interest income interest expense net portion capitalized income expense net earnings provision taxes income provision taxes income net earnings percent sales customers diluted net earnings per share common stock percent return average shareholders ' equity percent increase previous year sales customers diluted net earnings per share supplementary expense data cost materials services total employment costs depreciation amortization maint repairs total tax expense supplementary balance sheet data property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders ' equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands table adjusted reflect twoforone stock split periods adjusted include effects alza merger net interest income also included cost materials services category includes taxes income payroll property business taxes dollars millions except per share figures table caption c c c c c c sales customers domestic sales customers international total sales cost products sold selling marketing administrative expenses research expense purchased inprocess research development interest income interest expense net portion capitalized income expense net earnings provision taxes income provision taxes income net earnings percent sales customers diluted net earnings per share common stock percent return average shareholders ' equity percent increase previous year sales customers diluted net earnings per share supplementary expense data cost materials services total employment costs depreciation amortization maintenance repairs total tax expense supplementary balance sheet data property plantand equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders ' equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands table adjusted reflect twoforone stock split periods adjusted include effects alza merger net interest income also included cost materials services category includes taxes income payroll property business taxes text document document typeex sequence filenameyexvtxt descriptionsubsidiaries text exhibit subsidiaries johnson johnson new jersey corporation domestic international subsidiaries shown certain us subsidiaries international subsidiaries named significant aggregate johnson johnson parent table caption jurisdiction name subsidiary organization c us subsidiaries dimensional pharmaceuticals inc delaware dp investments inc delaware alza corporation delaware alza land management inc delaware biosense webster inc california centocor inc pennsylvania codman shurtleff inc new jerseycordis corporation florida cordis international corporation delaware cordis llc delaware crescendo pharmaceuticals corporation delaware depuy disc inc delaware depuy inc delaware depuy mitek inc massachusetts depuy orthopaedics inc indiana depuy products inc indiana depuy spine inc ohio depuy spine sales limited partnership massachusetts diabetes diagnostics inc delaware ethicon endosurgery inc ohio ethicon endosurgery llc new mexico ethicon endosurgery services lp texas ethicon inc new jersey ethicon llc delaware gynopharma inc delaware heartport inc delaware independence technology llc new jersey iso merger corp delaware janssen finance company florida janssen inc delaware janssen ortho llc delaware janssen pharmaceutica inc pennsylvania janssen pharmaceutica products lp new jersey jjhc inc delaware johnson johnson baby products inc delaware johnson johnson consumer companies inc new jersey johnson johnson development corporation new jersey johnson johnson finance corporation new jersey johnson johnson health care systems inc new jersey table table caption jurisdiction name subsidiary organization c johnson johnson international new jersey johnson johnson japan inc new jersey johnson johnson merck consumer pharmaceuticals co new jersey johnson johnson middle east inc new jersey johnson johnson pharmaceutical research development llc new jersey johnson johnson professional co pr inc delaware johnson johnson services inc new jersey johnson johnson urban renewal associates new jersey johnson johnson vision care inc florida joint medical products corporation delaware lifescan inc california lifescan llc delaware mcneilppc inc new jersey middlesex assurance company limited vermont neutrogena corporation delaware nitinol development corporation california noramco inc georgia omj pharmaceuticals inc delaware orapharma inc delaware ortho biologics llc delaware ortho biotech holding corp delaware ortho biotech inc new jersey ortho biotech products lp new jersey orthoclinical diagnostics inc new york orthomcneil finance co florida orthomcneil pharmaceutical inc delaware rutan realty llc new jersey scios inc delaware splenda inc delaware teramed corporation delaware therakos inc florida tylenol company new jersey winthorpe valentine inc delaware international subsidiaries abello farmacia sl spain alza ireland limited ireland apsis sarl francecentra medicamenta otc srl italy cilag ag switzerland cilag ag international switzerland cilag de mexico de rl de cv mexico cilag holding ag switzerland cordis de mexico sa de cv mexico cordis europa nv netherlands cordis italia spa italy cordis medizinische apparate gmbh germany table table caption jurisdiction name subsidiary organization c cordis sa france cordis sarl switzerland depuy ace sarl switzerland depuy australia pty ltd australia depuy france sa france depuy international ltd united kingdom depuy intl holdings ltd united kingdom depuy ireland limited ireland depuy italia spa italy depuy japan kk japan depuy orthopadie gmbh germany depuy orthopedie sa france depuy spine sarl switzerland depuy uk holdings limited united kingdom ethicon endosurgery europe gmbh germany ethicon gmbh germany ethicon ireland limited ireland ethicon limited scotland ethicon sas france ethicon spa italy ethnor proprietary limited south africa greiter ag switzerland greiter international ag switzerland inverness medical limited scotland janssen animal health bvba belgium janssencilag denmark janssencilag norway janssencilag ab sweden janssencilag ag switzerland janssencilag bv netherlands janssencilag ca venezuela janssencilag egypt ltd egypt janssencilag farmaceutica lda portugal janssencilag farmaceutica ltda brazil janssencilag gmbh germany janssencilag ltd united kingdom janssencilag nv belgium janssencilag oy finland janssencilag pharmaceutical saci greece janssencilag pharma gmbh austria janssencilag pty limited australia janssencilag sa spain janssencilag sa de cv mexico janssencilag sas france janssencilag spa italy janssen internationaal cvba belgium janssen korea ltd korea table table caption jurisdiction name subsidiary organization c janssenortho inc canada janssen pharmaceutica limited thailand janssen pharmaceutica nv belgiumjanssen pharmaceutica pty limited south africa janssen pharmaceutical kk japan janssen pharmaceutical limited ireland jc healthcare ltd israel jhc nederland bv netherlands johnson johnson ab sweden johnson johnson ag switzerland johnson johnson china investment co ltd china johnson johnson china ltd china johnson johnson comercio e distribuicao ltda brazil johnson johnson consumer france sas france johnson johnson consumer nvsa belgium johnson johnson de argentina sace argentina johnson johnson de colombia sa colombia johnson johnson de venezuela sa venezuela johnson johnson european treasury company ireland johnson johnson egypt sae egypt johnson johnson finance limited england johnson johnson financial services gmbh germany johnson johnson gesellschaft mbh austria johnson johnson gmbh germany johnson johnson group holdings gmbh germany johnson johnson hellas sa greece johnson johnson holding ab sweden johnson johnson holding gmbh germany johnson johnson hong kong limited hong kong johnson johnson inc canada johnson johnson international financial services company ireland johnson johnson international sa france johnson johnson investments limited england johnson johnson ireland limited ireland johnson johnson kenya limited kenya johnson johnson kft hungary johnson johnson kk japan johnson johnson korea ltd korea johnson johnson lda portugal johnson johnson limited india johnson johnson ltd england johnson johnson management limited england johnson johnson medical bv netherlands johnson johnson medical china ltd china johnson johnson medical korea limited korea johnson johnson medical limited scotland johnson johnson medical mexico sa de cv mexico table table caption jurisdiction name subsidiary organization c johnson johnson medical nvsa belgium johnson johnson medical pty limited south africa johnson johnson medical pty limited australia johnson johnson medical sa argentina johnson johnson morocco sa morocco johnson johnson new zealand limited new zealand johnson johnson pacific pty limited australia johnson johnson pakistan private limited pakistan johnson johnson philippines inc philippines johnson johnson poland sp z oo poland johnson johnson private limited zimbabwe johnson johnson products inc canada johnson johnson produtos profissionais ltda brazil johnson johnson proprietary limited south africa johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson research pty limited australia johnson johnson sa spain johnson johnson sa de cv mexico johnson johnson sdn bhd malaysia johnson johnson spa italy johnson johnson spolsro czech republic johnson johnson swiss finance company limited united kingdom johnson johnson taiwan ltd taiwan johnson johnson thailand ltd thailandjohnson johnson vision care ireland limited ireland laboratoires martin johnson johnson msd sas france laboratoires polive snc france lifescan canada ltd canada mcneil consumer nutritionals ltd england medos sa switzerland neutrogena provence sarl france obtech medical ag switzerland omj ireland limited ireland omj manufacturing limited ireland orthoclinical diagnostics united kingdom orthoclinical diagnostics gmbh germany orthoclinical diagnostics kk japan orthoclinical diagnostics nv belgium orthoclinical diagnostics sa france orthoclinical diagnostics spa italy penta pty limited australia pt johnson johnson indonesia indonesia shanghai johnson johnson limited china shanghai johnson johnson pharmaceuticals ltd china tasmanian alkaloids pty ltd australia table table caption jurisdiction name subsidiary organization c tibotec bvba belgium tibotec pharmaceuticals ltd ireland tibotecvirco comm va belgium vania expansion snc france virco bvba belgium woelm pharma gmbh co germany xianjanssen pharmaceutical ltd china table text document document typeex sequence filenameyexvtxt descriptionconsent independent accountants text exhibit consent independent accountants hereby consent incorporation reference registration statements form file form file report dated january except fifth thirteenth paragraphs note dates february february respectively relating financial statements johnson johnson appears annual report shareholders incorporated annual report also consent incorporation reference report dated january relating financial statement schedule appears pricewaterhousecoopers llp pricewaterhousecoopers llp new york new york march text documentdocument typeexa sequence filenameyexvwatxt descriptioncertification ceo text exhibit certification chief executive officer rule aa securities exchange act pursuant section sarbanesoxley act william c weldon certify reviewed annual report johnson johnson registrant based knowledge annual report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered annual report based knowledge financial statements financial information included annual report fairly present material respects financial condition results operations cash flows registrant periods presented annual report registrant 's certifying officer responsible establishing maintaining disclosure controls procedures defined exchange act rule ae registrant designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating registrant including consolidated subsidiaries made known us others within entities particularly period annual report prepared b evaluated effectiveness registrant 's disclosure controls procedures presented annual report conclusions effectiveness disclosure controls procedures end period covered report based evaluation c disclosed report change registrant 's internal control financial reporting occurred registrant 's recent fiscal quarter materially affected reasonably likely materially affect registrant 's internal control financial reporting registrant 's certifying officer disclosed based recent evaluation internal control financial reporting registrant 's auditors audit committee registrant 's board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect registrant 's ability record process summarize report financial information b fraud whether material involves management employees significant role registrant 's internal control financial reporting william c weldon william c weldon chief executive officer date march text document documenttypeexb sequence filenameyexvwbtxt descriptioncertification cfo text exhibit b certification chief financial officer rule aa securities exchange act pursuant section sarbanesoxley act robert j darretta certify reviewed annual report johnson johnson registrant based knowledge annual report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered annual report based knowledge financial statements financial information included annual report fairly present material respects financial condition results operations cash flows registrant periods presented annual report registrant 's certifying officer responsible establishing maintaining disclosure controls procedures defined exchange act rule ae registrant designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating registrant including consolidated subsidiaries made known us others within entities particularly period annual report prepared b evaluated effectiveness registrant 's disclosure controls procedures presented annual report conclusions effectiveness disclosure controls procedures end period covered report based evaluation c disclosed report change registrant 's internal control financial reporting occurred registrant 's recent fiscal quarter materially affected reasonably likely materially affect registrant 's internal control financial reporting registrant 's certifying officer disclosed based recent evaluation internal control financial reporting registrant 's auditors audit committee registrant 's board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect registrant 's ability record process summarize report financial information b fraud whether material involves management employees significant role registrant 's internal control financial reporting robert j darretta robert j darretta chief financial officer date march text document document typeexasequence filenameyexvwatxt descriptioncertification ceo text exhibit certification chief executive officer pursuant section sarbanesoxley act undersigned william c weldon chief executive officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies company 's annual report fiscal year ended december report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company william c weldon william c weldon chief executive officer dated march certification furnished sec report form k pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act text document document typeexb sequence filenameyexvwbtxt descriptioncertification cfo text exhibit b certification chief financial officer pursuant section sarbanesoxley act undersigned robert j darretta chief financial officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies company 's annual report fiscal year ended december report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company robert j darretta robert j darretta chief financial officer dated march certification furnished sec report form k pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act textdocument document typeexb sequence filenameyexvwbtxt descriptioncautionary statement text exhibit b cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements company may time time make certain forwardlooking statements publiclyreleased materials written oral forwardlooking statements relate strictly historical current facts anticipate results based management 's plans subject uncertainty forwardlooking statements may identified use words like plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance company 's strategy growth product development regulatory approvals market position expenditures forwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncertainties materialize actual results could vary materially company 's expectations projections investors therefore cautioned place undue reliance forwardlooking statements furthermore company assumes obligation update forwardlooking statements result new information future events developments important factors could cause company 's actual results differ company 's expectations forwardlooking statements follows economic factors including inflation fluctuations interest rates currency exchange rates potential effect fluctuations revenues expenses resulting margins competitive factors including technological advances achieved patents attained competitors well new products introduced competitors including fact continued competition us procrit topselling product company 's portfolio new competition expected cypher drugeluting stent challenges company 's patents competitors allegations company 's products infringe patents third parties could potentially affect company 's competitive position ability sell products question require payment past damages future royalties particular generic drug firms filed abbreviated new drug applications seeking market generic forms company 's key pharmaceutical products prior expiration applicable patents covering products event company successful defending resulting lawsuits generic versions product issue introduced resulting substantial market share revenue losses financial distress bankruptcies experienced significant customers suppliers could impair ability case may purchase company 's products pay products previously purchased meet obligations company supply arrangements impact political economic conditions due terrorist attacks us parts world us military action overseas well instability financial markets could result terrorism military actions interruptions computer communication systems including computer viruses could impair company 's ability conduct business communicate internally customers health care changes us countries resulting pricing pressures including continued consolidation among health care providers trends toward managed care health care cost containment government laws regulations relating sales promotion reimbursement pricing generally government laws regulations affecting us foreign operations including relating securities laws compliance trade monetary fiscal policies taxes price controls regulatory approval new products licensing patent rights including particular proposed amendments hatchwaxman act implementation recently enacted medicare prescription drug improvement modernization act competition research involving development improvement new existing products processes particularly significant results time time product process obsolescence development new improved products important company 's success areas business difficulties inherent product development including potential inability successfully continue technological innovation complete clinical trials obtain regulatory approvals united states abroad gain maintain market approval products possibility encountering infringement claims competitors respect patent intellectual property rights preclude delay commercialization product significant litigation adverse company including product liability claims patent infringement claims antitrust claims health care industry come increased scrutiny government agencies state attorney generals resulting investigations prosecutions carry risk significant civil criminal penalties including debarment government business product efficacy safety concerns resulting product recalls regulatory action part fda foreign counterparts declining sales impact business combinations including acquisitions divestitures internally company externally pharmaceutical health care industries issuance new revised accounting standards american institute certified public accountants financial accounting standards board securities exchange commission foregoing list sets forth many factors could impact upon company 's ability achieve results described forwardlooking statements investors understand possible predict identify factors consider list complete statement potential risks uncertainties company identified factors list permitted private securities litigation reform act text document secdocument end privacyenhanced message